Section 3 of 6
Product information and disease description
399 evidence topics · 168 sources
Product description
Phase of product development
Summary: development stage and regulatory timing
Lanifibranor is an investigational oral product in phase 3 development for adults with noncirrhotic MASH and F2 to F3 fibrosis. The last participant completed the final 72-week visit of the NATiV3 phase 3 trial, and NATiV3 topline results were expected in the fourth quarter of 2026. Inventiva states that, if the results are favorable, it anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. The FDA granted Fast Track designation and, in October 2020, Breakthrough Therapy designation, and the Chinese NMPA granted Breakthrough Therapy designation in December 2023. Company guidance for NATiV3 topline results changed across successive releases: from the second half of 2024 to the second half of 2025, the first half of 2026, the beginning of the second half of 2026, the second half of 2026, and the fourth quarter of 2026.
Regulatory status: Submission planned; NDA for accelerated approval planned for the first half of 2027
Launch: Anticipated in 2028
NATiV3 topline timing: fourth quarter of 2026, as of October 2026
NATiV3 last patient visit, September 2026
Approval status: not approved by any regulatory authority
Accelerated approval and conditional authorization: completion of the trial required for full approval
Planned phase 3 outcome trial in MASH with compensated cirrhosis
FDA Fast Track designation for NASH, September 2019
FDA Breakthrough Therapy designation for NASH, October 2020
FDA Fast Track designation extended to NASH with compensated cirrhosis, September 2021
China NMPA Breakthrough Therapy designation for MASH, December 2023
EU PRIME designation
No evidence found.
Development in China and Japan: regulatory approval in China to rest on NATiV3; pivotal trial in Japan and South Korea after NATiV3 results
NATiV3 topline timing, September 2021, superseded in September 2022
NATiV3 topline timing, September 2022, superseded in December 2023
NATiV3 topline timing, December 2023, superseded in July 2024
NATiV3 topline timing, July 2024, superseded in October 2024
NATiV3 topline timing, October 2024 to November 2025, superseded in March 2026
Product information
Generic, brand name and therapeutic class of product
Generic name, chemical name, and identifiers
| Field | Quoted record |
|---|---|
| International nonproprietary name (Latin) | “lanifibranorum” |
| International nonproprietary name (English) | “lanifibranor” |
| Chemical name | “4-[1-(1,3-benzothiazole-6-sulfonyl)-5-chloro-1H-indol- 2-yl]butanoic acid” |
| Functional description | “peroxisome proliferator-activated receptors (PPAR) agonist” |
| Molecular formula | “C19H15ClN2O4S2” |
| CAS registry number | “927961-18-0” |
| INN list | “Proposed INN: List 116” |
Development code: IVA337
| Field | Quoted record |
|---|---|
| Arm | “Lanifibranor (IVA 337) (800 mg/day)” |
| Arm | “Lanifibranor (IVA 337) (1200 mg/day)” |
Brand name
No evidence found.
Regulatory applicants outside the United States: CTTQ in Greater China and Hepalys in Japan and South Korea
Therapeutic class: oral pan-PPAR agonist
Dosage forms and strengths
Investigational dosage form: 400 mg film-coated immediate-release tablet
Tablets per daily dose in NATiV3: two or three 400 mg tablets
Packaging of the investigational tablets: HDPE bottles
Storage and stability of the investigational tablets
Bioequivalence study in healthy volunteers, France, February to May 2026
Commercial strengths and package sizes
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
WHO INN functional description: peroxisome proliferator-activated receptors agonist
Indication
Population of the pivotal NATiV3 trial: adults with biopsy-proven noncirrhotic MASH and F2 to F3 fibrosis
Company wording of the target population: MASH with moderate and advanced fibrosis
Indication named in the FDA designations: treatment of MASH
Population expansion planned: MASH with compensated cirrhosis
Proposed labeling
No evidence found.
Pharmacology
Mechanism of action
Pan-PPAR agonist: company description of isoform activation
Company rationale for activating all three isoforms
Chemical class: indole sulfonamide small molecule
“Here, we describe the identification and synthesis of novel indole sulfonamide derivatives that activate the three peroxisome proliferator activated receptor (PPAR) isoforms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Starting with a PPARα activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Transactivation potency and maximal effect at human PPAR isoforms
“In the transactivation assay (see Supporting Information), IVA337 acts as a pan‐PPAR agonist with moderate and balanced activity on the three PPAR isoforms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVA337 50% effective concentration (EC50) levels for the human PPARs (hPPARs) were 1.63E‐06 M for PPARα, 8.49E‐07 M for PPARδ, and 2.28E‐07 M for PPARγ.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The maximal effect (Emax) reached 100% for both hPPARα and hPPARδ and 80% for hPPARγ when compared to fenofibrate, GW501516, and rosiglitazone, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The potency of IVA337 for PPARα and PPARγ is in the same range as that of fenofibrate (EC50, 2 µM; PPARα) and pioglitazone (EC50, 0.3 µM; PPARγ), two clinically used and well‐tolerated PPAR agonists with a good efficacy/safety ratio.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Isoform potency and PPARγ efficacy relative to pioglitazone
“This study was designed so as to provide functional and structural insights into the potency, efficacy, and selectivity against PPARα/δ/γ of lanifibranor, seladelpar, and elafibranor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EC50 values for PPARα/δ/γ were in small ranges (0.4–5 µM in Figure 1B and 3–14 µM in Figure 2A,B), and therefore, lanifibranor in clinical doses seems to be able to activate all PPAR subtypes at once.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the fact that its efficacies for PPARγ activation often match with those of pioglitazone (Figure 2A vs. Figure 2I, Figure 2B vs. Figure 2J, and Figure 3B vs. Figure 3F), PPARγ-related undesirable side effects (such as weight gain, edema, bone loss, and congestive heart failure) [42] should be closely monitored in the case of lanifibranor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Isoform-specific pathways attributed to each PPAR subtype
“Among other effects, PPARα agonists reduce TG levels by increasing mitochondrial FA β-oxidation; PPARβ/δ ligands increase HDL-C levels, have anti-inflammatory effects and improve glucose utilization of skeletal muscle, while PPARγ activity exerts antifibrotic effects on activated hepatic stellate cells and improves IS in liver, adipose tissue and skeletal muscle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical metabolic-immune improvements with lanifibranor indeed substantiate the pan-PPAR activating mechanism across all three subtypes, exemplified by the effects on TG, HDL-C and IR reflecting mainly PPARα, β/δ and γ mediated mechanisms, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical efficacy compared with single and dual PPAR agonists
Hepatic stellate cell proliferation and activation
“IVA337 dose dependently and completely inhibited PDGF‐induced hHSC proliferation (Fig. 7A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the selective PPAR agonists demonstrated only partial effects up to the highest concentrations (Fig. 7A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic macrophage activation: PPARδ-dependent effect
“Lanifibranor attenuated the accompanying inflammatory activation in both murine palmitic acid-stimulated bone marrow-derived macrophages, as well as patient-derived circulating monocytes, in a PPARδ-dependent fashion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PPARδ agonism and lanifibranor directly modulate macrophage activation, but not infiltration, thereby synergizing with beneficial metabolic effects of PPARα/γ agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Adiponectin as a marker of PPARγ engagement: phase 1 multiple ascending dose study in healthy participants
Adiponectin, lipids, glucose, and fluid retention markers at day 28: phase 2a study in participants with type 2 diabetes on metformin
| Mean (SD) percent change from baseline at day 28 | Lanifibranor 400 mg (n=17) | Lanifibranor 800 mg (n=15) | Lanifibranor 1400 mg (n=15) | Placebo (n=14) |
|---|---|---|---|---|
| Triglycerides | “–19.7 (33.9)” | “–20.8 (23.5)” | “–31.7 (31.2)” | “–5.81 (27.6)” |
| HDL-C | “13.4 (15.3)” | “16.7 (17.2)” | “27.7 (25.9)” | “2.52 (12.2)” |
| Pro-insulin | “–26.7 (35.6)” | “–21.1 (45.0)” | “–37.4 (26.3)” | “–3.28 (49.9)” |
| Mean (SD) value reported for change from baseline at day 28 | Lanifibranor 400 mg (n=17) | Lanifibranor 800 mg (n=15) | Lanifibranor 1400 mg (n=15) | Placebo (n=14) |
|---|---|---|---|---|
| Ankle foot volume, cm3 | “3.75 (14.51)” | “–5.31 (15.51)” | “3.91 (11.14)” | “–5.42 (11.07)” |
| Body weight change at Day 28, kg | “0.55 (1.97)” | “0.11 (1.72)” | “0.94 (2.05)” | “–0.36 (2.68)” |
| Hemoglobin, g/L | “–5.63 (4.81)” | “–5.04 (6.75)” | “–5.96 (5.55)” | “–3.70 (5.29)” |
Pharmacodynamic biomarkers used for dose selection
Adiponectin, triglycerides, HDL cholesterol, and diastolic blood pressure after 24 weeks: NATIVE
“This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With placebo only 10% had moderate, and none high increase (Supplementary Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adiponectin is a pleiotropic adipokine and PPARγ downstream mediator, while PPARα activity may affect adiponectin signaling through receptor upregulation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fasting high density lipoprotein cholesterol (HDL-C) increased significantly at treatment week 4 (TW4), maintained until EOT: patients receiving lanifibranor 1200 mg and 800 mg had an AMD at EOT of 0.10 mmol/L (95%CI: 0.03 to 0.16, p = 0.003, equivalent to 3.9 mg/dL) and 0.16 mmol/L (95%CI: 0.09 to 0.22, p < 0.001, equivalent to 6.2 mg/dL), respectively (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Systolic BP did not change significantly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NT-proBNP, hemoglobin, and the PPARγ class history of edema and heart failure
“While PPARγ-associated weight gain is thus indicative of maturation of adipose tissue, some contributing effect on fluid retention is suggested by the treatment effect on NT-proBNP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Past pure PPARγ agonists such as the thiazolidinediones pioglitazone and rosiglitazone are effective for glycemic control and improving IR, but also have been associated with an increased risk of edema and heart failure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clinical evidence for congestion in patients on lanifibranor in NATIVE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Important risks identified for the PPAR agonist class
Plasma volume and cardiac effects in rats compared with rosiglitazone, muraglitazar, and tesaglitazar
Hepatic, muscle, and adipose tissue insulin sensitivity by clamp: participants with type 2 diabetes and MASLD
Liver sinusoidal endothelial cell capillarisation in NATIVE liver biopsies
“We analysed CD34 expression, a marker of LSEC capillarisation, on liver biopsies from patients considered for inclusion in the NATIVE trial at baseline (n = 249), and after 24 weeks of placebo or lanifibranor (n = 173).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improvement in periportal score was more common in patients treated with lanifibranor than in those treated with placebo, with a dose–response effect (placebo: 7.5%. lanifibranor 800 mg: 18.5%. lanifibranor 1,200 mg: 23.2%. p = 0.025, Fig. 5C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both patients and rats with MASLD, lanifibranor treatment was associated with improvement in liver endothelial phenotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Portal pressure and fibrosis in cirrhotic rat models
“TAA-cirrhotic rats receiving lanifibranor showed significantly lower portal pressure compared with vehicle-treated animals (-15%; p = 0.003) without decreasing portal blood flow, indicating improved hepatic vascular resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, lanifibranor-treated TAA-rats showed decreased ascites, improved LSEC and HSC phenotypes, ameliorated hepatic microvascular function, reduced hepatic inflammation, and significant fibrosis regression (-32%; p = 0.020).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Electrocardiographic findings in healthy volunteers and patients with type 2 diabetes
Pharmacokinetics
Clinical pharmacology studies described in the NATIVE protocol
Absorption: solubility class and food effect
Time to maximum concentration, half-life, dose proportionality, and steady state in humans
Less than dose-proportional exposure at 400, 800, and 1400 mg: participants with type 2 diabetes
Distribution and plasma protein binding
Metabolism: circulating parent drug and main human metabolites
Elimination: faecal excretion in the radiolabeled study
Supratherapeutic multiple ascending dose study in healthy men
QT/QTc study in 217 healthy participants at 1200 and 2400 mg/day
Pharmacokinetic study in healthy Chinese adults at 800 and 1200 mg
Phase 1 study in Japan: 32 participants dosed once daily for 14 days
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Older adults: exposure in elderly compared with young healthy participants
Chinese adults: bridging study and ethnic differences
Renal impairment: effect on kidney function
Renal impairment: renal function eligibility criteria
Renal impairment: dedicated pharmacokinetic study
No evidence found.
Hepatic impairment: compensated liver disease eligibility criteria
Hepatic impairment: cirrhosis and abnormal synthetic liver function as exclusion criteria
Hepatic impairment: dedicated pharmacokinetic study
No evidence found.
Autoimmune liver or thyroid disease: exclusion added after a suspected unexpected serious adverse reaction
Type 2 diabetes: histologic and glycemic response in participants with diabetes
Prediabetes: participants without type 2 diabetes
“Among 144 patients without T2D, 47 (33%) had prediabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With prediabetes, FG decreased at EOT to <5.6 mmol/L in 71% (95%CI: 48 to 95, p = 0.009) of patients on lanifibranor 1200 mg, 67% (95%CI: 45 to 88, p = 0.013) on 800 mg versus 11% (95%CI: 0 to 32) on placebo, indicating return to normoglycemia in the majority of lanifibranor-treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heart failure: exclusion criteria
Anemia: hemoglobin exclusion threshold
Pregnancy: placental distribution and reproductive toxicity in animals
Pregnancy, breastfeeding, and contraception: trial requirements
Ovulation resumption: listed among important risks of the therapeutic class
Pediatric population: age criterion of 18 years or older
Pediatric population: pediatric studies
No evidence found.
Lactose intolerance: lactose monohydrate excipient
Drug/Drug, drug/disease interactions
Effects of other drugs on Lanifibranor
Metabolizing enzymes in vitro: CYP2C8, CYP2C19, CYP3A4, and UGT isoforms
Strong CYP2C8 inducers and inhibitors: exclusion and washout before treatment
Strong CYP2C8 inducers and inhibitors: prohibited concomitant medications, with rifampin, gemfibrozil, and clopidogrel as examples
Protocol amendment driven by preliminary results of drug-drug interaction study 337HVPK21014
Concomitant PPAR agonists: fibrates and thiazolidinediones excluded
Published results of drug-drug interaction study 337HVPK21014
No evidence found.
Effects of Lanifibranor on other drugs
In vitro inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP2B6
In vitro inhibition of UGT isoforms and drug transporters
Simvastatin: clinical interaction study S337.1.002
CYP2B6 and CYP2C8 substrates: excluded by protocol amendment
Empagliflozin: combination assessed for interaction on glycemic control
Dosing and administration
Dosage
Doses in NATiV3: 800 mg or 1200 mg once daily
| Arm | Registered regimen |
|---|---|
| Lanifibranor 800 mg/day | “2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food” |
| Lanifibranor 1200 mg/day | “3 Lanifibranor tablets 400mg with food” |
| Placebo | “3 Placebo to match tablets with food” |
Company description of the dosing regimen
Doses of 800 mg and 1200 mg once daily for 24 weeks and the biomarker basis for their selection
Single-center phase 2 study in type 2 diabetes and MASLD: 800 mg
Dose modification and treatment interruption in the trials
Commercial dose and dose adjustment for special populations
No evidence found.
Administration
Oral film-coated 400 mg immediate-release tablet with a breakline
Administration of 3 tablets with food in the morning
Administration with breakfast at site visits
Storage conditions for the investigational tablets
Access and distribution
Manufacturing by third parties for clinical and commercial supply
U.S. commercial infrastructure, pricing, and reimbursement still to be established
Pre-commercial preparation, 2025 to 2026
Company market access goal: monotherapy and combination use
Commercialization rights in Greater China: CTTQ
Commercialization rights in Japan and South Korea: Hepalys Pharma
Specialty pharmacy or distribution network
No evidence found.
Co-prescribed/Concomitant therapies
Background therapies permitted at a stable dose in NATiV3: GLP-1 receptor agonists, SGLT2 inhibitors, vitamin E, and statins
Therapies excluded in NATiV3: approved NASH or obesity treatment, insulin, thiazolidinediones, and fibrates
Company position: NATiV3 assesses lanifibranor with GLP-1 receptor agonists and SGLT2 inhibitors
Combination with empagliflozin in LEGEND: no further study planned
Effect of Lanifibranor on quality measures
HEDIS Glycemic Status Assessment for Patients With Diabetes (GSD)
HbA1c change with lanifibranor in participants with MASH and type 2 diabetes, LEGEND interim analysis
Product-specific effect on quality measures
No evidence found.
Product comparison
Lanifibranor: company statement of its position among PPAR agonists
Approved and phase 3 competitors named by Inventiva in its annual report
Lanifibranor with GLP-1 receptor agonists: company presentation of potential synergy
Resmetirom (REZDIFFRA): indication and accelerated approval
Resmetirom: mechanism of action, partial thyroid hormone receptor-beta agonist
Resmetirom: oral once-daily dosing based on body weight
Resmetirom: month 12 histology in Trial 1 (NCT03900429), 888 F2 and F3 participants, missing biopsy counted as nonresponse
| Endpoint at month 12 | Placebo (N=294) | REZDIFFRA 80 mg (N=298) | REZDIFFRA 100 mg (N=296) |
|---|---|---|---|
| Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist A (%) | “13” | “27” | “36” |
| Difference vs. placebo (95% CI), Pathologist A | Not applicable | “14 (8, 20)” | “23 (16, 30)” |
| Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist B (%) | “9” | “26” | “24” |
| Difference vs. placebo (95% CI), Pathologist B | Not applicable | “17 (11, 23)” | “15 (9, 21)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist A (%) | “15” | “23” | “28” |
| Difference vs. placebo (95% CI), Pathologist A | Not applicable | “8 (2, 14)” | “13 (7, 20)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist B (%) | “13” | “23” | “24” |
| Difference vs. placebo (95% CI), Pathologist B | Not applicable | “11 (5, 17)” | “11 (5, 17)” |
Resmetirom: MAESTRO-NASH week 52 primary analysis population of 966 participants
Semaglutide (WEGOVY): MASH indication and accelerated approval
Semaglutide: mechanism of action, GLP-1 receptor agonist
Semaglutide: subcutaneous once-weekly maintenance dosing for MASH
Semaglutide: week 72 histology in Study 11 (NCT04822181), 800 F2 and F3 participants, reference-based multiple imputation
| Endpoint at week 72 | Placebo (N=266) | WEGOVY injection (N=534) | Difference vs. placebo (95% CI) |
|---|---|---|---|
| Resolution of steatohepatitis and no worsening of liver fibrosis, response rate (%) | “34” | “63” | “29 (21, 36)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, response rate (%) | “22” | “37” | “14 (8, 21)” |
| Resolution of steatohepatitis and improvement in liver fibrosis, response rate (%) | “16” | “33” | “17 (10, 23)” |
Semaglutide: phase 3 part 1 interim analysis at week 72 in the first 800 of 1197 participants
Efruxifermin: acquisition of Akero Therapeutics by Novo Nordisk completed in December 2025
Efruxifermin: phase 3 trial in F2 or F3 MASH (NCT06215716), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “Akero Therapeutics, Inc” |
| Status | “Recruiting” |
| Study start (actual) | “2023-12-01” |
| Primary completion (estimated) | “2033-02” |
| Enrollment (estimated) | “1650” |
| Primary outcome, cohort 1 | “Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis” |
| Primary outcome | “Event-free survival” |
Efruxifermin: HARMONY phase 2b week 24 histology, liver biopsy analysis set and full analysis set
“HARMONY is a multicentre, randomised, double-blind, placebo-controlled, 96-week, phase 2b trial that was initiated at 41 clinics in the USA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the LBAS (n=113), eight (20%) of 41 patients in the placebo group had an improvement in fibrosis of at least 1 stage and no worsening of NASH by week 24 versus 15 (39%) of 38 patients in the efruxifermin 28 mg group (risk ratio [RR] 2·3 [95% CI 1·1-4·8]; p=0·025) and 14 (41%) of 34 patients in the efruxifermin 50 mg group (2·2 [1·0-5·0]; p=0·036).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the FAS (n=128), eight (19%) of 43 patients in the placebo group met this endpoint versus 15 (36%) of 42 in the efruxifermin 28 mg group (RR 2·2 [95% CI 1·0-4·8]; p=0·033) and 14 (33%) of 43 in the efruxifermin 50 mg group (1·9 [0·8-4·3]; p=0·123).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pegozafermin: acquisition of 89bio by Roche, agreement in September 2025 and tender offer completed in October 2025
Pegozafermin: ENLIGHTEN-Fibrosis phase 3 trial (NCT06318169), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “Hoffmann-La Roche” |
| Status | “Recruiting” |
| Study start (actual) | “2024-03-13” |
| Primary completion (estimated) | “2029-02” |
| Enrollment (estimated) | “1350” |
| Primary outcome | “Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52” |
| Primary outcome | “Number of Participants With Resolution of Steatohepatitis Without Worsening of Fibrosis at Week 52” |
| Primary outcome | “Time to First Occurrence of Disease Progression” |
Pegozafermin: ENLIVEN phase 2b week 24 histology, full analysis population with multiple imputation
“In this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial, we randomly assigned patients with biopsy-confirmed NASH and stage F2 or F3 (moderate or severe) fibrosis to receive subcutaneous pegozafermin at a dose of 15 mg or 30 mg weekly or 44 mg once every 2 weeks or placebo weekly or every 2 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 222 patients who underwent randomization, 219 received pegozafermin or placebo. The percentage of patients who met the criteria for fibrosis improvement was 7% in the pooled placebo group, 22% in the 15-mg pegozafermin group (difference vs. placebo, 14 percentage points; 95% confidence interval [CI], −9 to 38), 26% in the 30-mg pegozafermin group (difference, 19 percentage points; 95% CI, 5 to 32; P = 0.009), and 27% in the 44-mg pegozafermin group (difference, 20 percentage points; 95% CI, 5 to 35; P = 0.008). The percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs. placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Missing end-point data (for 28 patients) were imputed with the use of multiple imputation by means of logistic regression with all collected outcomes. The full analysis population included all the enrolled patients who had undergone randomization and received at least one dose of pegozafermin or placebo and who had confirmed fibrosis stage F2 or F3 (indicating moderate or severe fibrosis) and a nonalcoholic fatty liver disease activity score of at least 4 at baseline, as assessed on independent review by a three-pathologist panel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efimosfermin alfa (GSK): once-monthly FGF21 analog in phase 3, FDA Breakthrough Therapy and EMA PRIME designations in April 2026
Efimosfermin alfa: ZENITH-1 phase 3 trial in F2 or F3 MASH (NCT07221227), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “GlaxoSmithKline” |
| Status | “Recruiting” |
| Study start (actual) | “2025-10-24” |
| Primary completion (estimated) | “2028-03-29” |
| Enrollment (estimated) | “1200” |
| Primary outcome | “Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52” |
| Primary outcome | “Time from randomization to an adjudicated composite liver-related clinical outcome” |
Efimosfermin alfa: phase 2 trial in F2 or F3 MASH with a safety primary endpoint at week 24
“Participants were randomly assigned 1:1 to efimosfermin 300 mg or placebo administered by subcutaneous injection every 4 weeks (Q4W) over 24 weeks, stratified by MASH fibrosis stage (F2 vs F3 stage).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was safety and tolerability (ie, treatment-emergent adverse events, changes from baseline to week 24 in blood pressure and heart rate, and the incidence of grade 3 and grade 4 laboratory abnormalities at week 24), analysed in all participants who received at least one dose.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between May 4, 2023, and March 22, 2024, of 1171 participants screened, 84 participants were randomly assigned to efimosfermin 300 mg Q4W (n=43) or placebo (n=41)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events were reported in 29 (67%) of 43 participants receiving efimosfermin and 22 (55%) of 40 receiving placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survodutide: LIVERAGE phase 3 trial in noncirrhotic F2 to F3 MASH (NCT06632444), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “Boehringer Ingelheim” |
| Status | “Recruiting” |
| Study start (actual) | “2024-10-14” |
| Primary completion (estimated) | “2031-12-27” |
| Enrollment (estimated) | “1800” |
| Primary outcome, part 1 | “Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score” |
| Primary outcome, part 1 | “Part 1: At least a 1-point improvement in fibrosis stage with no worsening of MASH” |
Survodutide: phase 2 week 48 histology in F1 to F3 MASH, 293 participants who received at least one dose
“In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: SYNERGY-Outcomes phase 3 master protocol in high-risk MASLD selected by noninvasive tests (NCT07165028), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “Eli Lilly and Company” |
| Status | “Recruiting” |
| Study start (actual) | “2025-10-15” |
| Primary completion (estimated) | “2030-08” |
| Enrollment (estimated) | “4500” |
| Primary outcome | “Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)” |
Tirzepatide: SYNERGY-NASH phase 2 week 52 histology in F2 or F3 MASH, 190 randomized with missing biopsies imputed
“We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pemvidutide: PERFORMA phase 3 trial in F2 to F3 MASH initiated in August 2026
| Field | Quoted record |
|---|---|
| Sponsor | “Altimmune, Inc.” |
| Status | “Recruiting” |
| Study start (actual) | “2026-07-30” |
| Primary completion (estimated) | “2028-12” |
| Enrollment (estimated) | “1800” |
| Arms | “Pemvidutide 1.8 mg” |
| Arms | “Pemvidutide 2.4 mg” |
Pemvidutide: IMPACT phase 2b week 24 histology in F2 or F3 MASH, intention-to-treat population
“IMPACT is an ongoing 48-week international, randomised, double-blind, placebo-controlled, phase 2b trial in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The dual primary endpoints were MASH resolution without worsening of fibrosis or at least one stage liver fibrosis improvement without worsening of MASH at 24 weeks in the intention-to-treat population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1·2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0·0001), and 45 (52%) of 85 patients in the 1·8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0·0001). Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1·2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0·59), and 30 (36%) of 85 patients in the 1·8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0·27).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MASH at this timepoint.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Denifanstat: phase 3 FASCINATE-3 trial withdrawn and further MASH development deferred pending non-dilutive financing
| Field | Quoted record |
|---|---|
| Sponsor | “Sagimet Biosciences Inc.” |
| Status | “Withdrawn” |
| Why stopped | “Business decision” |
| Enrollment (actual) | “0” |
Denifanstat: FASCINATE-2 phase 2b week 52 histology in F2 or F3 MASH, intention-to-treat population
“participants aged 18 years and older with biopsy-confirmed MASH and stage F2 or F3 fibrosis were randomly assigned (2:1) to receive either 50 mg oral denifanstat or placebo once per day for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the ITT population, 42 (38%) of 112 participants in the denifanstat group had a 2-point or greater improvement in NAS without a worsening of fibrosis versus nine (16%) of 56 participants in the placebo group (common risk difference 21·0%, 95% CI 8·1-33·9; p=0·0035). 29 (26%) of 112 participants in the denifanstat group showed MASH resolution with a 2-point or greater improvement in NAS without a worsening of fibrosis compared with six (11%) of 56 participants in the placebo group (common risk difference 13·0%, 0·7-25·3; p=0·0173).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cross-trial comparison of histologic response: company presentation, with its caveat that results may not be comparable
Cross-trial comparison of adiponectin change: lanifibranor, resmetirom, efruxifermin, and pegozafermin, with the authors’ caveat that results may not be comparable
| Product (trial, time point) | Dose | Absolute change in adiponectin from baseline at end of treatment, µg/ml |
|---|---|---|
| Lanifibranor (NATIVE, 24 weeks) | “800mg” | “+ 11.95 (8.97 to14.94)” |
| Lanifibranor (NATIVE, 24 weeks) | “1200mg” | “+ 17.12 (14.29 to 19.96)” |
| Resmetirom (MAESTRO-NASH, 52 weeks) | “80mg” | “+ 0.86 (0.19)” |
| Resmetirom (MAESTRO-NASH, 52 weeks) | “100mg” | “+ 1.1 (0.19)” |
| Efruxifermin (HARMONY, 24 weeks) | “28mg” | “+ 1.4(0.74 to 2.08)” |
| Efruxifermin (HARMONY, 24 weeks) | “50mg” | “+ 3.0(2.34 to 3.71)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “15mg” | “+ 1.1(0.7)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “30mg” | “+ 1.1(0.3)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “44mg” | “+ 1.2 (0.4)” |
Network meta-analysis of 29 randomized trials including lanifibranor, with the authors’ stated limitations
“We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 29 randomized controlled trials (n=9324) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from eligible studies were extracted as intention-to-treat (ITT) analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pegozafermin (RR: 3.46, CrI: 1.54–11.15), cilofexor + firsocostat (RR: 2.67, CrI: 1.05–8.13), denifanstat (RR: 1.94, CrI: 1.04–4.04), survodutide (RR: 1.86, CrI: 1.18– 3.28), obeticholic acid (RR: 1.85, CrI: 1.30–2.75), tirzepatide (RR: 1.77, CrI: 1.17–2.94), resmetirom (RR: 1.64, CrI: 1.27–2.20), and semaglutide (RR: 1.51, CrI: 1.23–1.90) were statistically better than placebo in achieving ≥1 stage of fibrosis improvement without worsening MASH (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pegozafermin (RR: 8.65, CrI: 2.63–59.42), survodutide (RR: 6.62, CrI: 3.13–17.97), tirzepatide (RR: 4.65, CrI: 2.31–10.66), efruxifermin (RR: 3.51, CrI: 1.83–8.17), liraglutide (RR: 3.23, CrI: 1.11–14.17), vitamin E + pioglitazone (RR: 3.03, CrI: 1.31–9.04), resmetirom (RR: 2.54, CrI: 1.86–3.55), pioglitazone (RR: 2.29, CrI: 1.41–4.03), denifanstat (RR: 2.03, CrI: 1.04–4.72), semaglutide (RR: 1.87, CrI: 1.60–2.24), and lanifibranor (RR: 1.93, CrI: 1.30–3.02) were statistically better than placebo in achieving MASH resolution without worsening fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, we acknowledge the modest number of trials with direct comparisons between pharmacological therapies, and the small number of trials for each agent; hence, most comparisons between treatments were based on indirect evidence; head-to-head trials versus other drugs should be considered to validate our findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparability between trials was further limited by their heterogeneity in design and population (eg, demographics and comorbidities).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | SUCRA, fibrosis improvement ≥1 stage without worsening MASH |
|---|---|
| Pegozafermin | “79.92”View highlighted excerpt for this quote |
| Denifanstat | “60.64”View highlighted excerpt for this quote |
| Survodutide | “59.89”View highlighted excerpt for this quote |
| Tirzepatide | “57.37”View highlighted excerpt for this quote |
| Efruxifermin | “56.20”View highlighted excerpt for this quote |
| Resmetirom | “50.14”View highlighted excerpt for this quote |
| Semaglutide | “47.04”View highlighted excerpt for this quote |
| Lanifibranor | “46.56”View highlighted excerpt for this quote |
Place of product in therapy
Disease description
Definition and etiology
Steatotic liver disease nomenclature: MASLD replaces NAFLD and MASH replaces NASH
“Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 75% of respondents of the external expert committee chose MASLD as the replacement term for NAFLD and 88% metabolic dysfunction–associated steatohepatitis (MASH) as the replacement term for NASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Persons with MASLD and steatohepatitis will be designated as metabolic dysfunction associated steatohepatitis (MASH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MASLD as a disease spectrum from steatosis to MASH, fibrosis, cirrhosis, and hepatocellular carcinoma
“Metabolic dysfunction-associated steatotic liver disease (MASLD) is the umbrella term that comprises metabolic dysfunction-associated steatotic liver, or isolated hepatic steatosis, through to metabolic dysfunction-associated steatohepatitis, the progressive necroinflammatory disease form that can progress to fibrosis, cirrhosis and hepatocellular carcinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MASLD is closely associated with insulin resistance, obesity, gut microbial dysbiosis and genetic risk factors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis staging retained under the new nomenclature, including MASH with stage 3 fibrosis
“The new names also allow for further characterisation of fibrotic severity, for example, MASH with stage 3 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease staging and severity are not altered by this process although it is anticipated that, in the near to medium term, disease staging will be achieved using noninvasive tests, which can be incorporated into further clarifications of disease stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
At-risk NASH defined as biopsy-proven NASH with stage 2 or higher fibrosis
Continuity of NAFLD and NASH evidence with MASLD and MASH: European registry and US NHANES overlap
“an analysis of the LITMUS consortium European was performed, which demonstrated that 98% of the existing registry cohort of patients with NAFLD would fulfill the new criteria for MASLD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“maintenance of the term, and clinical definition, of steatohepatitis ensures retention and validity of prior data from clinical trials and biomarker discovery studies of patients with NASH to be generalisable to individuals classified as MASLD or MASH under the new nomenclature, without impeding the efficiency of research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was 99% overlap in cases of NAFLD and MASLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among those with NAFLD or MASLD, 99.0% (95% CI 97.6%–99.6%) met the criteria for both NAFLD and MASLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiometabolic risk factors in the definition of MASLD: adult criteria
| Metabolic risk factor | Adult criteria |
|---|---|
| Overweight or obesity: body mass index | “≥25 kg/m2 (≥23 kg/m2 in people of Asian ethnicity)” |
| Overweight or obesity: waist circumference (Europeans) | “≥94 cm in men and ≥80 cm in women (Europeans)” |
| Overweight or obesity: waist circumference (South Asians and Chinese) | “≥90 cm in men and ≥80 cm in women (South Asians and Chinese)” |
| Dysglycaemia: prediabetes | “Prediabetes: HbA1c 39-47 mmol/mol (5.7-6.4%) or fasting plasma glucose 5.6-6.9 mmol/L (100-125 mg/dl)” |
| Type 2 diabetes | “Type 2 diabetes: HbA1c ≥48 mmol/mol (≥6.5%) or fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dl)”; “Treatment for type 2 diabetes” |
| Plasma triglycerides | “≥1.7 mmol/L (≥150 mg/dl) or lipid-lowering treatment” |
| HDL-cholesterol | “≤1.0 mmol/L (≤39 mg/dl) in men and ≤1.3 mmol/L (≤50 mg/dl) in women or lipid-lowering treatment” |
| Blood pressure | “≥130/85 mmHg or treatment for hypertension” |
Alcohol intake thresholds separating MASLD, MetALD, and alcohol-related liver disease
Etiology: type 2 diabetes, obesity, age, and menopausal status as risk factors for progressive fibrosis
“T2DM is the most impactful risk factor for the development of NAFLD, fibrosis progression, and HCC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NAFLD is closely linked to and often precedes the development of metabolic abnormalities (insulin resistance, dyslipidemia, central obesity, and hypertension).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: inherited risk, PNPLA3 and TM6SF2 variants, and heritability
“NAFLD and NASH have a heritable component that is estimated to be between 35%–61%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PNPLA3 gene is a major driver of NAFLD, NASH, cirrhosis, and HCC risk in individuals who have metabolic risk factors such as obesity, diabetes, and metabolic syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
US adults with newly coded NASH with F2 to F3 fibrosis: claims-based annual incidence, 2020
“In the base case, the annual incidence was calculated by dividing the projected number of newly coded patients with F2/F3 NASH in 2020 (73,085) in the US population by the total adult population (257,279,447), resulting in a rate of 28.4 cases per 100,000 adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“other diagnosed NASH incidence rates were obtained from analyses conducted using the Optum CDM and Veradigm® EHR (linked with Komodo Health claims), which provided a range of values (20.4–64.0 per 100,000 adults)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with NASH: incident and prevalent cases in 2017, Markov model
Adults with fatty liver developing NASH: paired biopsy and imaging meta-analysis of observational studies
“We screened 9,744 articles and included 54 studies involving 26,738 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, 31% of patients developed NASH after 4.7 years (incidence rate=7.4/100 person-years) whereas in 29% of those with NASH, resolution occurred after a median of 3.5 years (incidence rate=5.1/100 person-years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US incident NAFL cases, 2015 and projected to 2030, Markov model
Global NAFLD incidence in adults diagnosed by imaging: meta-analysis
“The overall incidence of NAFLD was estimated to be 46·9 cases per 1000 person-years (36·4-57·5); 70·8 cases per 1000 person-years (48·7-92·8) in men and 29·6 cases per 1000 person-years (20·2-38·9) in women (p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global NAFLD incidence in ultrasound-diagnosed cohorts: meta-analysis of 12 studies
“Incidence rates were reported in 12 studies involving a total sample size of 256,757 subjects at baseline with total PY of 800,853. The pooled incidence estimate of NAFLD was 48.89 per 1000 PY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled NAFLD incidence numerically increased by +58.0% from 37.41 per 1000 PY (95% CI: 24.36–57.06) in 1994–2006 to 59.11 per 1000 (39.64–87.26) in 2010–2014 survey year” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
US adults with NASH and non-cirrhotic F2 to F3 fibrosis: prevalence inputs of an eligible-population model
“In the base case, a NASH prevalence of 4.6% was modeled (range 1.3–14.2%). This value was multiplied by the proportion estimated to have non-cirrhotic MALF (i.e., 35%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, taking patient counts estimates using FIB-4 for F2 and F3 over the total subgroup patient count, we get (3735 + 2725)/18,612 ≈ 35% of the patients were diagnosed with F2/F3 NASH (Table 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assuming a 1-million commercial-member population, the resmetirom treatment-eligible population was estimated as 1255–1699 in Years 1–3 following approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with NASH and moderate to severe fibrosis: ICER budget impact population, 2023 to 2027
US adults meeting liberal and restrictive resmetirom eligibility criteria, NHANES 2017 to March 2020
“Two eligibility scenarios were examined: a liberal scenario requiring ALT >17 U/L for women or >20 U/L for men, controlled attenuation parameter (CAP) >280 dB/m, and liver stiffness measurement (LSM) >8 kPa; and a restrictive scenario requiring ALT >30 U/L for both sexes, CAP >280 dB/m, and LSM >10 kPa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An estimated 8.3 million (95% CI: 6.6–9.9 million) adults met the liberal eligibility criteria, while 2.3 million (95% CI: 1.4–3.2 million) met the restrictive criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among adults with T2DM, 3.5 million (95% CI: 2.4–4.5 million; 12.2%) met liberal, whereas 0.85 million (95% CI: 0.5–1.2 million; 3.0%) restrictive criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with NAFLD: at-risk NASH by FAST score (proxy for NAS of 4 or more and F2 or higher), NHANES 2017 to 2018
“Patients with a FAST score >0.35 were considered to have at-risk NASH, defined as NASH with NAFLD activity score ≥4 and fibrosis stage ≥2 on liver biopsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall prevalence of at-risk NASH was 11.6% (95% CI: 8.8–15.1) and was higher in males than females (15.8% vs. 6.5%; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated ~9 million people in the US have at-risk NASH and may benefit from active surveillance and therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with MASLD by liver stiffness: 8 to 12 kPa and 12 kPa or higher, NHANES 2017 to 2020
US adults aged 50 years or older with type 2 diabetes: MASLD, at-risk MASH, and cirrhosis, prospective cohort 2016 to 2023
“This prospective study enrolled adults age ≥ 50 with T2DM from primary care and endocrinology clinics in southern California from 2016 to 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with T2DM, the prevalence of MASLD, at-risk MASH and cirrhosis was 69.6%, 13.6%, and 6.8%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At-risk MASH was defined by an either positive MEFIB score (MRE > 3.3 kPa + Fib4 > 1.6), FAST score ≥ 0.67, or MAST score ≥ 0.242” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with SLD, MASLD, and MetALD, NHANES January 2017 to March 2020
“Among 7367 participants, 2549 met the new definition for SLD (mean age 51 years, 57.7% male, 63.2% non-Hispanic White; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated prevalence of SLD was 34.2% (95% CI 31.9%–36.5%): MASLD 31.3% (95% CI 29.2%–33.4%), MetALD 2.2% (95%CI 1.6–2.9%), ALD 0.7% (95%CI 0.5–0.9%) and etiology-specific or cryptogenic SLD 0.03% (95% CI 0.01%–0.08%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this national study, we estimate the prevalence of SLD to be 34.2% (ie, > 90 million US adults), with MASLD accounting for the majority (31.3%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with SLD and MASLD, age-adjusted, and advanced fibrosis in SLD, NHANES 2017 to 2023
“Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US general population with MASLD and MASLD-related cirrhosis, NHANES 2017 to 2020
“The prevalence of chronic liver disease etiologies was ALD 0.85%, MetALD 3.38%, CHB 0.23%, CHC 0.73%, ALD + viral hepatitis 0.16%, and MASLD 33.05%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with MASLD comprise the majority of US residents with cirrhosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
US adults with NAFLD and NASH: prevalence and clinically significant fibrosis in AASLD 2023 guidance
“The prevalence of NAFLD in adults is estimated to be 25%–30% in the general population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of NASH in the general population is challenging to determine with certainty; however, NASH was identified in 14% of asymptomatic patients undergoing colon cancer screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study also highlights that since the publication of a prior prospective prevalence study,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the prevalence of clinically significant fibrosis (stage 2 or higher fibrosis) has increased > 2-fold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US NAFLD and NASH cases with F3 to F4 fibrosis, 2015 and projected to 2030, Markov model
“The total NAFLD population in 2015 was estimated at 83.1 million cases (Fig. 3A), with a prevalence rate of 30.0% among the population aged ≥15 years and 25.8% among all ages. By 2030, the NAFLD population was projected to increase 21% to 100.9 million cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of NASH cases is projected to increase 63% from 16.52 million cases in 2015 to 27.00 million in 2030 (Fig. 3B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among NASH cases in 2015, an estimated 20% have F3/F4 fibrosis or advanced liver disease, encompassing approximately 3.31 million cases (Fig. 4). By 2030, this number is expected to increase over 160% to 7.94 million cases and will account for 29% of NASH cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with MASLD, MASH, and MASH with F2 or higher fibrosis, projected 2020 to 2050, microsimulation model
“The model predicted a steady increase in the prevalence of MASLD from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050. Cases of MASH would increase from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050. The number of cases of MASH and clinically significant fibrosis (ie, F≥F2, centrilobular and periportal fibrosis or more severe disease) were estimated to increase from 6.7 million to 11.7 million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global and North American NAFLD prevalence: meta-analysis of studies from 1990 to 2019
“Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 (p<0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across the entire study period (1990–2019), analysis of the regional prevalence rates showed a prevalence of 31.20% in North America and Australia (95% CI: 25.86%–37.08%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global and North American NASH prevalence: estimate from voluntarily biopsied NAFLD cohorts
“Subsequently, the NASH prevalence in the general population was estimated by multiplying the prevalence of NASH in the “voluntary biopsied NAFLD” group with the prevalence of NAFLD in the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our estimates suggest that the global NASH prevalence is 5.27% (SE: 2.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“North America [5.00% (2.50)]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of NASH among NAFLD patients is 16.02% (95% CI: 3.24%–52.08%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global NAFLD prevalence in adults diagnosed by imaging: meta-analysis
“The overall prevalence of NAFLD worldwide was estimated to be 32·4% (95% CI 29·9-34·9). Prevalence increased significantly over time, from 25·5% (20·1-31·0) in or before 2005 to 37·8% (32·4-43·3) in 2016 or later (p=0·013). Overall prevalence of NAFLD was significantly higher in men than in women (39·7% [36·6-42·8] vs 25·6% [22·3-28·8]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global NAFLD prevalence and metabolic comorbidities: meta-analysis of studies from 1989 to 2015
“Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global NAFLD prevalence forecast to 2040, hierarchical Bayesian model
UK Biobank participants with liver MRI: SLD, MASLD, and at-risk MASH
“At-risk MASH was defined as PDFF≥5% and cT1 ≥875 ms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 40,189 patients, 10,886 (27.0%) had a PDFF ≥5%, indicating SLD. Among patients with SLD, 1% had ALD, 89.0% had MASLD, 7.9% had MetALD and 2.2% had at-risk MASH. The at-risk MASH group, which included 0.6% of the general population, had the highest mean liver fat on MRI and the highest BMI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Fibrosis stage as the primary predictor of outcomes, with higher risk from F2 (at-risk NASH)
“Data from meta-analyses and pooled studies demonstrate that fibrosis and the presence of steatohepatitis are the primary predictors of disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, patients with NASH and at least stage 2 fibrosis (F2), referred to as “at-risk” NASH, have a demonstrably higher risk of liver-related morbidity and mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common causes of death in patients with NAFLD overall are cardiovascular disease (CVD) and nonhepatic malignancy, followed by liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bridging fibrosis and cirrhosis are associated with an exponentially greater risk of liver-related morbidity and mortality than earlier stages of fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause and liver-related mortality by fibrosis stage: meta-analysis of 14 articles, 17,301 participants with biopsy-proven NAFLD
“Medline and Embase databases were searched to include cohort studies reporting survival outcomes by fibrosis stage in biopsy-proven NAFLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 14 articles involving 17,301 patients with NAFLD were included. All-cause mortality at 1, 5, and 10 years for stage 0 to 2 fibrosis was 0.1%, 3.3%, and 7.7% vs 0.3%, 20.6%, and 41.5% for stage 4 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08–1.98), stage 3; HR, 1.96 (95% CI, 1.41–2.72), and stage 4; HR, 3.66 (95% CI, 2.65–5.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44–11.5), stage 3; HR, 7.59 (95% CI, 2.80–20.5), and stage 4; HR, 15.1 (95% CI, 5.27–43.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality rate ratios by fibrosis stage: meta-analysis of 5 cohorts, 1,495 participants with NAFLD
“1,495 NAFLD patients with 17,452 patient years of follow-up were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all-cause mortality and this risk increased with increase in the stage of fibrosis: stage 1, MRR, 1.58 (95% CI 1.19–2.11); stage 2, MRR, 2.52 (95% CI 1.85–3.42); stage 3, MRR, 3.48 (95% CI 2.51–4.83), and stage 4, MRR, 6.40 (95% CI 4.11–9.95).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results were more pronounced as the risk of liver-related mortality increased exponentially with increase in the stage of fibrosis: stage 1, MRR, 1.41 (95% CI 0.17–11.95); stage 2, MRR, 9.57 (95% CI 1.67–54.93); stage 3, MRR, 16.69 (95% CI 2.92–95.36); and stage 4, MRR, 42.30 (95% CI 3.51–510.34).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative risk of mortality and liver events, stage 4 versus stage 0: meta-analysis of 13 studies, 4,428 participants with NAFLD
“Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with no fibrosis (stage 0), unadjusted risk increased with increasing stage of fibrosis (stage 0 vs 4): all-cause mortality RR, 3.42 (95% CI, 2.63-4.46); liver-related mortality RR, 11.13 (95% CI, 4.15-29.84); liver transplant RR, 5.42 (95% CI, 1.05-27.89); and liver-related events RR, 12.78 (95% CI, 6.85-23.85).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Death or liver transplantation and liver-related events by fibrosis stage: 619 participants with biopsy-diagnosed NAFLD, median 12.6 years
“We performed a retrospective analysis of 619 patients diagnosed with NAFLD from 1975 through 2005 at medical centers in the United States, Europe, and Thailand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over a median follow-up of 12.6 years (range 0.3–35.1), 193 of the patients (33.2%) died or underwent liver transplantation. Features of liver biopsies significantly associated with death or liver transplantation included fibrosis stage 1 (HR, 1.88; 95% CI, 1.28, 2.77), stage 2 (HR, 2.89; 95% CI, 1.93, 4.33), stage 3 (HR, 3.76; 95% CI, 2.40, 5.89), and stage 4 (HR, 10.9; 95% CI, 6.06, 19.62) compared with stage 0” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-six patients (4.2%) developed liver-related events; fibrosis stage 3 (HR 14.2 [95% CI 3.38, 59.68]) and stage 4 (HR 51.5 [95% CI 9.87, 269.2]) compared to stage 0, were significantly associated with the events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths and liver-related complications per 100 person-years by fibrosis stage: prospective NASH CRN cohort, 1,773 adults, median 4 years
“A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality by histologic stage versus matched controls: Swedish nationwide biopsy cohort, 10,568 participants, median 14.2 years
“This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966–2017; n=10,568).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over a median of 14.2 years, 4,338 NAFLD patients died.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to controls, significant excess mortality risk was observed with simple steatosis (8.3/1000PY, aHR=1.71, 95%CI=1.64–1.79), non-fibrotic NASH (13.4/1000PY, aHR=2.14, 95%CI=1.93–2.38), non-cirrhotic fibrosis (18.4/1000PY, aHR=2.44, 95%CI=2.22–2.69) and cirrhosis (53.6/1000PY, aHR=3.79, 95%CI=3.34–4.30)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The excess mortality associated with NAFLD was primarily from extra-hepatic cancer (4.5/1000PY; aHR=2.16, 95%CI=2.03–2.30), followed by cirrhosis (2.7/1000PY; aHR=18.15, 95%CI=14.78–22.30), cardiovascular disease (1.4/1000PY; aHR=1.35, 95%CI=1.26–1.44) and hepatocellular carcinoma (HCC)(1.2/1000PY; aHR=11.12, 95%CI=8.65–14.30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Major adverse liver outcomes by fibrosis stage: Swedish cohort of 1,260 participants with non-cirrhotic NAFLD, median 13 years
“Patients (n = 1,260) with NAFLD without cirrhosis were diagnosed through biopsy or radiology, and had fibrosis estimated through vibration-controlled transient elastography, biopsy, or FIB-4 score between 1974 and 2020 and followed up through 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MALO occurred in 111 (8.8%, incidence rate = 5.9/1,000 person-years) patients with NAFLD and 197 (1.6%, incidence rate = 1.0/1,000 person-years) reference individuals during a median follow up of 13 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 20-year cumulative incidences of MALO were 2% for the reference population, 3% for patients with F0, and 35% for F3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adjusted hazard ratio (aHR) for F2, as determined by biopsy, was 2.9 (95% CI 1.5–5.5), and for F3 the aHR was 8.9 (95% CI 4.6–17.4), both compared with the reference group with F0–1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression to cirrhosis and all-cause mortality in non-cirrhotic MASH F2 and F3: US TARGET-NASH cohort, 2,378 participants
“Among the 2378 patients included in this analysis, 48% had MASH cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 1425 patients with non-cirrhotic MASH, there were 982 patients in the F0–F1 cohort, 281 patients in the F2 cohort, and 162 patients in the F3 cohort (Supplemental Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence rates of cirrhosis increased from 0.34/100PM in the F0–F1 cohort to 1.24/100PM in the F2 cohort and 6.62/100PM in the F3 cohort (Table 5). Unadjusted risk of progressing to cirrhosis was highest among those with F3 (HR, 95% CI; 18.66, 10.97–31.73) and 3.74 times higher with F2 (HR, 95% CI; 3.74, 2.00–6.98) versus F0–F1 (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause mortality was associated with disease severity and incidence rates increased from 0.14/100PM in the F0–F1 cohort to 0.3/100PM in the F2 cohort, 0.42/100PM in the F3 cohort, 2.02/100PM in the compensated cirrhosis cohort and 4.62/100PM in the decompensated cirrhosis cohort (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis was supported by Novo Nordisk Inc., Plainsboro, NJ.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis progression and regression rates and times by stage: meta-analysis of 54 paired biopsy or imaging studies
“Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3 and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively. Rates estimated from RCTs were higher than those from observational studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with F2, a similar proportion progressed, regressed, or remained stable (32%, 37%, and 31%, respectively) after 5 years. Patients with F3 regressed more often than progressed, 32% vs. 22%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled incidence of progression from F0, F1, F2, and F3 were 6.5, 6.9, 5.8, and 4.5/100 person-years, respectively (Table 3). Pooled incidence for regression from F1, F2, F3, and F4 were 2.5, 4.6, 6.0, and 4.7/100 person-years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis progression rate in NASH versus NAFL: meta-analysis of 11 paired biopsy cohorts, 411 participants
“We identified 11 cohort studies including 411 patients with biopsy-proven NAFLD (150 with NAFL and 261 with NASH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 2145.5 person-years of follow up, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had improvement in fibrosis stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings correspond to 1 stage of progression over14.3 years for patients with NAFL (95% CI, 9.1–50.0 years) and 7.1 years for patients with NASH (95% CI, 4.8–14.3 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis progression in NASH and mortality rates in NAFLD and NASH: global meta-analysis
“Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause and cause-specific mortality among adults with NAFLD: global meta-analysis
“Among the NAFLD population, the pooled mortality rate (n=3) in studies that had used ultrasound or serum diagnostic method was 12.60 per 1000 PY (6.68–23.67) for all-cause mortality; 4.20 per 1000 PY (1.34–7.05) for cardiac-specific mortality; 2.83 per 1000 PY (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 per 1000 PY (0.00–2.21) for liver-specific mortality (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression from steatosis to steatohepatitis, effect of type 2 diabetes, and cause-specific mortality by histologic stage
US NAFLD-related decompensated cirrhosis, hepatocellular carcinoma, and liver deaths, projected 2015 to 2030, Markov model
“Incident decompensated cirrhosis is forecasted to increase by 168%, from 39,320 cases annually in 2015 to 105,430 cases in 2030” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“incident HCC cases are expected to increase by 137% from 5,160 to 12,240 in 2030 (Fig. 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver deaths are projected at 78,300 in 2030, an increase of 178% from 2015 (Fig. 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US MASLD-related decompensated cirrhosis, liver cancer, and liver transplant, projected 2020 to 2050, microsimulation model
Pathophysiology
Substrate overload and lipotoxicity
“In defining pathogenic drivers of NAFL and NASH, a useful conceptual framework is that the liver’s capacity to handle the primary metabolic energy substrates, carbohydrates and fatty acids, is overwhelmed, leading to accumulation of toxic lipid species” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These metabolites induce hepatocellular stress, injury and death, leading to fibrogenesis and genomic instability that predispose to cirrhosis and hepatocellular carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When fatty acids are either supplied in excess or their disposal is impaired, they may serve as substrates for the generation of lipotoxic species that provoke ER stress and hepatocellular injury.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The presence and severity of NAFL and NASH are substantially determined by factors that govern the supply and disposition of fatty acids, diacylglycerols, ceramides, cholesterol, phospholipids, and other intrahepatic lipids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulin resistance and adipose tissue dysfunction
“Insulin resistance is nearly universal in patients with NAFLD and is present in the liver, adipose tissue, and muscle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adipose tissue insulin resistance is characterized by increased release of free fatty acids from adipocytes (lipolysis) in the fasting state” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A primary disease driver may be an oversupply of fat to adipocytes such that their ability to store triglyceride without inducing cell stress is exceeded, which activates inflammatory pathways and causes insulin resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic de novo lipogenesis and dietary sugars
“The metabolic mechanisms leading to NAFLD reflect an imbalance of energy metabolism in the liver: excess energy, mostly in the form of carbohydrates and fat, entering the liver relative to the ability of the liver to oxidize this energy to CO2 or export it as very-low-density lipoproteins (VLDLs) (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although excess consumption of any food can lead to development of NAFLD, mono- and disaccharides, especially fructose, sucrose, and high-fructose corn syrup, which is ubiquitous in processed foods, can activate programs of hepatic de novo lipogenesis that further exacerbate NAFLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Skeletal muscle insulin resistance, one of the earliest defects associated with metabolic syndrome and prediabetes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular injury, inflammation, and macrophage activation
“Hepatocellular injury in NASH is characterized by endoplasmic reticulum (ER) stress” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“likely modulate the hepatocyte’s development of lipotoxic stress, injury and inflammation. The relative contribution of these defects in individuals with NASH is not clarified yet and likely varies among individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The response of the liver to lipotoxic injury includes activation and recruitment of resident macrophages, which further contributes to hepatocellular injury and stellate cell activation as part of a complex interplay among hepatic cell types.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional factors such as hepatocyte uric acid production, exposure to products derived from the gut microbiome, and perhaps low hepatic magnesium levels, may also contribute to the NASH phenotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrogenesis through hepatic stellate cell activation
“The accumulation of extracellular matrix in the liver, which leads to progressive fibrosis, cirrhosis, portal HTN and liver failure, is the major cause of liver-related death in patients with NAFLD. Fibrogenesis is driven by signaling from stressed or injured hepatocytes and activated macrophages (Kupffer cells in the liver), leading to activation of resident hepatic stellate cells into myofibroblasts to produce matrix proteins faster than they are degraded” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Another NASH-specific pathway is through the PNPLA3-I148M variant’s effects directly on stellate cell fibrogenesis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic modifiers of hepatocyte lipid handling
“Although in some patients, the development and progression of NASH are driven by substrate overload and insulin resistance, in other patients, disease progression is heavily influenced by genetic factors impacting hepatocyte lipid handling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The I148M polymorphism of PNPLA3 impairs lipolysis of triglyceride in lipid droplets,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recently, lossof-function variants in HSD17B13, a gene that encodes an enzyme that also localizes to lipid droplets in hepatocytes, have been linked to protection against NASH, progressive fibrosis, and HCC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PPAR-mediated pathways as therapeutic targets: adipocyte insulin sensitivity, fatty acid oxidation, and inflammation
“improve adipocyte insulin sensitivity [eg, peroxisome proliferator-activated receptor (PPAR)γ ligands]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, peroxisome proliferator–activated receptor gamma (PPARγ) ligands (for example, pioglitazone), a specialized type of nuclear receptor ligand, enhance adipocyte storage of fat and improve NASH, albeit at the expense of increased peripheral fat stores and weight gain, as shown in clinical trials of these drugs in patients with type 2 diabetes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PPARα component increases fatty acid oxidation, whereas the PPARδ component has anti-inflammatory effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PPARγ ligands (for example, pioglitazone, a member of the family of thiazolidinedione class of drugs) have been studied in several trials and improve steatosis, inflammation and hepatocellular ballooning as well as hepatic fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Liver biopsy: reference standard for grading and staging, AASLD 2023 practice guidance
“Although liver biopsy assessment remains the reference standard for the grading and staging of NASH, it has important limitations related to risk, cost, and resource utilization. Therefore, liver biopsies for grading and staging of NASH are not consistently performed in clinical practice and should be reserved for specific clinical scenarios (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver biopsy should be considered when NITs suggest significant fibrosis (≥ F2), especially if additional evaluation suggests the presence of “at-risk” NASH (eg, using FAST, MEFIB, MAST, or cT1), NIT assessment is indeterminate, aminotransferases are persistently elevated (> 6 mo), or additional/alternate diagnoses are suspected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liver biopsy: required for a definite diagnosis of steatohepatitis, EASL-EASD-EASO 2024 guideline
Liver biopsy: only reliable means to diagnose NASH, AGA clinical care pathway
“A liver biopsy is currently the only reliable means to diagnose NASH and is the reference standard for fibrosis staging. However, liver biopsy may not be feasible to obtain in a significant number of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liver biopsy: reserved to the specialist, ADA Standards of Care 2026
“While liver biopsy remains the gold standard for the diagnosis of MASH, its indication is reserved to the discretion of the specialist within an interprofessional team approach due to high costs and potential for morbidity associated with this procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary risk assessment with FIB-4: thresholds, AASLD 2023 practice guidance
“When the fibrosis-4 index (FIB-4) is <1.3, patients can be followed in the primary care setting and reassessed periodically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients older than age 65, a FIB-4 cutoff of > 2.0 should be used. FIB-4 has low accuracy in those under age 35; thus, secondary assessment should be considered in those <35 with increased metabolic risk or elevated liver chemistries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with FIB4 ≥ 1.3, a secondary assessment should be done [preferentially vibration-controlled elastography (VCTE) or Enhanced Liver Fibrosis (ELF) initially] or the patient referred for further risk stratification (if being seen in a nongastroenterology/hepatology setting). Direct referral to gastroenterology/hepatology should be considered in those with aminotransferases persistently (> 6 mo) above normal to exclude other causes of liver disease or when FIB4 > 2.67 due to the increased risk of clinically significant fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, a change in FIB-4 status category from low risk (< 1.3) to intermediate risk (1.3–2.67) to high risk (> 2.67) may be used to assess clinical progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary risk assessment with FIB-4: thresholds and false negatives, EASL-EASD-EASO 2024 guideline
Primary risk assessment with FIB-4: thresholds, AGA clinical care pathway
“Previous studies have shown that FIB-4 score <1.3 (<2.0 in those older than 65 years) can reliably exclude advanced fibrosis in patients with NAFLD, with a negative predictive value of ≥90%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with FIB-4 score >2.67 are at high risk for advanced fibrosis,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The remaining 30%-40% of patients with an FIB-4 test would likely have values in the indeterminate range (ie, 1.3–2.67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening with FIB-4 in type 2 diabetes or prediabetes: ADA Standards of Care 2026
“4.22a Screen adults with type 2 diabetes or with prediabetes, particularly those with obesity or other cardiometabolic risk factors or established cardiovascular disease, for their risk of having or developing cirrhosis related to metabolic dysfunction–associated steatohepatitis (MASH) using a calculated fibrosis-4 index (FIB-4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“4.23 Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A value of <1.3 is considered low risk of having advanced fibrosis (F3–F4) and for developing adverse liver outcomes, while ≥1.3 is considered as having a higher probability of at-risk MASH clinically significant fibrosis (≥F2) and increased risk of adverse liver outcomes. A value of >2.67 confers a high risk of having advanced fibrosis (F3–F4), and referral to the liver specialist is warranted without additional testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In individuals with diabetes ≥65 years of age, higher cutoffs for FIB-4 have been recommended (1.9–2.0 rather than ≥1.3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aminotransferases: frequently normal in clinically significant fibrosis
“Aminotransferase levels are frequently normal in patients with advanced liver disease due to NASH and should not be used in isolation to exclude the presence of NASH with clinically significant fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A screening strategy relying on elevated plasma aminotransferases >40 units/L would miss most individuals with MASH in these settings, as at-risk MASH with clinically significant fibrosis (≥F2) is frequently observed with plasma aminotransferases below the commonly used cutoff of 40 units/L” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vibration-controlled transient elastography: liver stiffness thresholds, AASLD 2023 practice guidance
“A recent meta-analysis suggested that a VCTE-derived liver stiffness measurement (LSM) <8 kPa can be used to rule out advanced fibrosis, especially if used sequentially after FIB-4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSMs by VCTE between 8 and 12 kPa may be associated with fibrotic NASH, and LSM > 12 kPa is associated with a high likelihood of advanced fibrosis, although the positive predictive value is low (range: 0.34–0.71).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In identifying patients with cirrhosis, a sequential approach with a FIB-4 > 3.48 and LSM by VCTE ≥ 20 kPa had a specificity of 90%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vibration-controlled transient elastography: liver stiffness thresholds, AGA clinical care pathway
“In a study of 450 consecutive adults who underwent liver biopsy and FibroScan for suspected NAFLD at 7 centers, the Youden cutoff value for F≥F2 was 8.2 kPa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A value of >12.1 kPa on VCTE indicates that clinically significant fibrosis is likely, with positive predictive values of 76% and 88% in patients seen in diabetes and hepatology clinic populations, respectively, although the positive predictive value can be low in primary care populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients with discordant or indeterminate LSM results (ie, 8.0–12.0 kPa) in primary care and endocrine clinics be referred to hepatology where, like high-risk patients, they might need to undergo either a liver biopsy or MRE for further diagnostic evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vibration-controlled transient elastography and ELF: thresholds in type 2 diabetes or prediabetes, ADA Standards of Care 2026
“An LSM value of <8.0 kPa has a good negative predictive value to exclude advanced fibrosis (≥F3–F4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the LSM is ≥8.0 kPa, the risk for advanced fibrosis (≥F3-F4) is higher and such individuals should be referred to the hepatologist” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with ELF ≥9.8 are considered at high risk of having MASH with advanced liver fibrosis (≥F3–F4) and therefore are at risk for adverse liver outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An ELF <9.8 suggests an individual is at low risk of advanced liver fibrosis and may be followed in the nonspecialty clinic with repeat testing in ≥2 years but may need repeat testing more often if ELF is between 9.2 and 9.7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enhanced Liver Fibrosis test: thresholds, AASLD 2023 practice guidance
“The ELF panel is a proprietary blood test consisting of three elements involved in matrix turnover: hyaluronic acid, tissue inhibitor of metalloproteinase-1, and N-terminal procollagen III peptide. An ELF score of ≥ 9.8 reliably identifies patients with NAFLD at increased risk of progression to cirrhosis and liver-related clinical events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Note that in patients with confirmed or suspected advanced fibrosis, an ELF ≥ 11.3 is a predictor of future liver-related events and is approved for this purpose; use of other ELF cutoffs in secondary risk assessment is based on expert option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Magnetic resonance elastography: accuracy and thresholds, AASLD 2023 practice guidance
“MRE is more sensitive than VCTE in the detection of fibrosis stage ≥ 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although MRE is not a first-line approach to risk stratification in a patient with NAFLD, it can be an important tool if clinical uncertainty exists, if there is a need for concomitant cross-sectional imaging, or when other elastography techniques are unavailable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An LSM by MRE ≥ 5 kPa is suggestive of cirrhosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Note that the units for LSM by VCTE and MRE are both kilopascals, but the scales are different.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rule-out and rule-in cut-offs of non-invasive tests for fibrosis and at-risk MASH, EASL-EASD-EASO 2024 guideline
| Non-invasive test | Rule-out cut-off | Rule-in cut-off |
|---|---|---|
| FIB-4 | “F3: 1.3” | “F3: 2.67” |
| ELF | “F3: 7.7” | “F3: 9.8” |
| VCTE liver stiffness | “F3: 8 kPa” | “F3: 12 kPa” |
| MEFIB (MRE combined with FIB-4) | “F2: MRE <3.3 kPa and FIB-4 <1.6” | “F2: MRE ≥3.3 kPa and FIB-4 ≥1.6” |
FibroScan-AST score for at-risk NASH: rule-out and rule-in cut-offs
“The most predictive model combined LSM, CAP, and AST, and was designated FAST (FibroScan-AST).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cutoff for sensitivity (≥0·90) was 0·35 and for specificity (≥0·90) was 0·67 in the derivation cohort” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selection of resmetirom candidates with non-invasive tests: AASLD 2024 guidance update
Selection of semaglutide candidates with non-invasive tests: AASLD 2025 guidance update
Diagnosis rate of noncirrhotic NASH with moderate to advanced fibrosis: US population calculator for resmetirom eligibility
“Published analyses suggest a diagnosis rate of ~ 10% (range 3.3–14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimation of the treatment-eligible population for resmetirom depends importantly on NASH diagnosis rates, which are predicted to be < 15% in the 3 years after drug approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, from additional analysis of NHANES data, it is estimated that 14.3% of prevalent patients with F2/F3 NASH have received a diagnosis of liver disease in a clinical setting (based on survey responses)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of diagnosed NASH: US adults, National Health and Wellness Survey 2016
“Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 2016 prevalence of diagnosed NASH among the US adult population was 0.15%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported liver disease awareness: US adults with MASLD and with liver stiffness 8 to 15 kPa, NHANES 2017 to 2023
“This study utilized the NHANES data cycle 2017–2020 and 2021–2023, a nationally representative survey of the noninstitutionalized U.S. population conducted by the National Center for Health Statistics (NCHS), which included vibration-controlled transient elastography (VCTE) data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with MASLD and LS 8–15 kPa were considered resmetirom-eligible in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Awareness of liver disease among individuals with MASLD remained low, with 5.8% (95% CI: 4.5%–7.2%) pre-pandemic and 6.7% (95% CI: 5.4%–8.1%) late-pandemic reporting awareness (p=0.36). Among those eligible for resmetirom, awareness was 12.1% (95% CI: 5.4%–18.8%) pre-pandemic and 10.3% (95% CI: 6.4%–14.2%) late-pandemic (p=0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Underdiagnosis of at-risk MASH in type 2 diabetes or prediabetes
“Clinicians underestimate the prevalence of at-risk MASH and do not consistently implement appropriate screening strategies in people with prediabetes or type 2 diabetes, thus missing a chance to establish an early diagnosis. This pattern of underdiagnosis is compounded by sparse referral to specialists and inadequate prescription of medications with potential efficacy in MASH” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Asymptomatic course: detection by imaging or liver chemistries
“In most patients, NAFLD is asymptomatic or associated with vague symptoms, often leaving patients undiagnosed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NAFLD are most commonly referred with incidentally noted hepatic steatosis on imaging or elevated liver chemistries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Physician-reported signs and symptoms survey: US adults with MASH, 2019 and 2022
“We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fourteen prespecified individual physician-reported features of MASH were evaluated by the survey: fatigue, sleep disturbance, insomnia, general weakness, unexplained weight loss, hair loss, changes to personality, memory loss, jaundice, aching/discomfort in upper right abdomen, itchy skin, swelling in the legs/ankles/feet, tendency to bleed and bruise more easily, and swelling of the abdomen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 14 reported signs and symptoms, 11 were significantly associated with both physician-stated fibrosis stage and/or AASLD-derived risk category.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
|---|---|---|---|---|
| None | “167 (39.4)”View highlighted excerpt for this quote | “58 (41.1)”View highlighted excerpt for this quote | “6 (20.0)”View highlighted excerpt for this quote | “9 (11.0)”View highlighted excerpt for this quote |
Constitutional symptoms: fatigue, sleep disturbance, and general weakness
“Non-specific symptoms of fatigue, sleep disturbance, and general weakness associated with MASH and other conditions predicted work impact in low-risk MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In all patients, fatigue was the most reported symptom (48.1%, n = 1,268/2,636) followed by sleep disturbance (25.3%, n = 667/2,636), and general weakness (23.7%, n = 625/2,636; Table S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fatigue and pruritus: adults with bridging fibrosis or compensated cirrhosis due to NASH, STELLAR 3 and 4 baseline
“Specifically, PROs (Short Form–36, Chronic Liver Disease Questionnaire–NASH, Euro‐Qol 5 Dimension, and Work Productivity and Activity Impairment instruments) were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conclusion: Clinically significant fatigue and pruritus are common in patients with advanced NASH, and these symptoms negatively affect PROs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fatigue, pruritus, and sleep disorders: adults with MASLD in the Global NAFLD/MASLD Registry
“Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Abdominal and skin symptoms: right upper quadrant discomfort, pruritus, and jaundice
“MASH has been associated with symptoms such as fatigue, abdominal pain, and poor sleep quality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
|---|---|---|---|---|
| Aching/discomfort in upper right abdomen | “43 (10.1)”View highlighted excerpt for this quote | “15 (10.6)”View highlighted excerpt for this quote | “2 (6.7)”View highlighted excerpt for this quote | “23 (28.0)”View highlighted excerpt for this quote |
| Itchy skin | “35 (8.3)”View highlighted excerpt for this quote | “13 (9.2)”View highlighted excerpt for this quote | “5 (16.7)”View highlighted excerpt for this quote | “10 (12.2)”View highlighted excerpt for this quote |
| Jaundice | “14 (3.3)”View highlighted excerpt for this quote | “3 (2.1)”View highlighted excerpt for this quote | “1 (3.3)”View highlighted excerpt for this quote | “8 (9.8)”View highlighted excerpt for this quote |
Cognitive symptoms: memory loss and changes to personality
“Obesity and cognitive impairment are also common in individuals with MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
|---|---|---|---|---|
| Memory loss | “11 (2.6)”View highlighted excerpt for this quote | “3 (2.1)”View highlighted excerpt for this quote | “0 (0.0)”View highlighted excerpt for this quote | “7 (8.5)”View highlighted excerpt for this quote |
| Changes to personality | “9 (2.1)”View highlighted excerpt for this quote | “4 (2.8)”View highlighted excerpt for this quote | “0 (0.0)”View highlighted excerpt for this quote | “4 (4.9)”View highlighted excerpt for this quote |
“Patients were grouped as: early fibrosis (stage 0–2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3–4) with additional CVRM comorbidities (AFwC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with AFwC had significantly higher symptom burden compared with those with EFnoC across multiple symptoms (fatigue, p = 0.0006; itchy skin, p = 0.0191; emotional impact, p = 0.0073; activity limitations, p <0.0001; cognitive symptoms, p = 0.0012; and social impact, p = 0.0007; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric symptoms: anxiety and depression in adults with diagnosed NASH
“After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More NASH patients reported anxiety (37.5% vs. 25.5%, p = 0.006) and depression (43.4% vs. 30.1%, p = 0.004), but sleep difficulties did not differ between cohorts (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical examination: features of insulin resistance and of advanced liver disease
“Body fat distribution (eg, android vs. gynoid, lipodystrophic), features of insulin resistance (eg, dorsal-cervical fat pad, acanthosis nigricans), features of advanced liver disease (eg, firm liver, splenomegaly, prominent abdominal veins, ascites, gynecomastia, spider angiomata, palmar erythema)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Initial evaluation of such patients should include screening for metabolic comorbidities, assessment of alcohol intake, and exclusion of other causes of liver disease as well as physical examination to identify signs of insulin resistance and advanced liver disease (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Signs of fluid retention, bleeding, and hepatic decompensation
| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
|---|---|---|---|---|
| Swelling in legs, ankles, feet | “42 (9.9)”View highlighted excerpt for this quote | “11 (7.8)”View highlighted excerpt for this quote | “1 (3.3)”View highlighted excerpt for this quote | “20 (24.4)”View highlighted excerpt for this quote |
| Swelling of abdomen | “26 (6.1)”View highlighted excerpt for this quote | “1 (0.7)”View highlighted excerpt for this quote | “0 (0.0)”View highlighted excerpt for this quote | “16 (19.5)”View highlighted excerpt for this quote |
| Tendency to bleed and bruise more easily | “9 (2.1)”View highlighted excerpt for this quote | “1 (0.7)”View highlighted excerpt for this quote | “0 (0.0)”View highlighted excerpt for this quote | “6 (7.3)”View highlighted excerpt for this quote |
“The principal outcomes included death from any cause, hepatic decompensation (clinically apparent ascites, overt encephalopathy, or variceal hemorrhage),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Encephalopathy (in 30 patients) and ascites (in 19) were the most common new decompensation events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Cirrhosis: prevalence in US adults with MASLD, NHANES 2017 to 2020
“We used National Health and Nutrition Examination Surveys (NHANES 2017-2020) to estimate the prevalence of cirrhosis and clinically significant (CS)-portal hypertension in alcohol-associated liver disease (ALD), MetALD, viral hepatitis to include chronic hepatitis B (CHB) and chronic hepatitis C (CHC), and metabolic dysfunction-associated steatotic liver disease (MASLD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of cirrhosis in the United States is 2.6% while the prevalence of CS-portal hypertension is 0.98%. Individuals with MASLD comprise the majority of US residents with cirrhosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cirrhosis: progression to clinical decompensation
“Those with cirrhosis require biannual screening for HCC as well as screening for varices and monitoring for signs or symptoms of decompensation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic decompensation and hepatocellular cancer by fibrosis stage: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2
“A total of 1773 adults with NAFLD were followed for a median of 4 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included adults who had liver biopsies that could be evaluated and that revealed NAFLD and who had at least one follow-up visit after 48 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Projected decompensated cirrhosis and hepatocellular carcinoma: US NAFLD population, 2015 to 2030 model
“Incidence of decompensated cirrhosis will increase 168% to 105,430 cases by 2030, while incidence of HCC will increase by 137% to 12,240 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Projected changes in NAFLD‐related cirrhosis, advanced liver disease, and liver‐related mortality were quantified through 2030.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular carcinoma: incidence in US veterans with NAFLD
“We compared 296,707 NAFLD patients with 296,707 matched controls. During 2,382,289 person-years [PY] of follow-up, 490 NAFLD patients developed HCC (0.21/1000 PY). HCC incidence was significantly higher among NAFLD patients vs. controls (0.02/1000 PY; hazard ratio, 7.62, 95% confidence interval=5.76–10.09). Among patients with NAFLD, those with cirrhosis had the highest annual incidence of HCC (10.6 /1000 PY).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In medical record reviews, 20% of NAFLD patients with HCC had no evidence of cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We conducted a retrospective cohort study from a total of 130 facilities in the Veterans Health Administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular carcinoma without cirrhosis: systematic review and meta-analysis of NAFLD-related HCC
“Of 3631 records identified, 61 studies (done between January, 1980, and May, 2021; 94 636 patients) met inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A higher proportion of patients with NAFLD-related hepatocellular carcinoma did not have cirrhosis (38·5%, 95% CI 27·9–50·2) compared with patients with hepatocellular carcinoma secondary to other causes (14·6%, 8·7–23·4; p<0·0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular carcinoma risk with F3 fibrosis and surveillance recommendations
Liver transplantation: NASH/MASH share of US and European transplant recipients, 2000 to 2022
“Data from 2 large LT registries: the US Scientific Registry of Transplant Recipients (SRTR) and the European Liver Transplant Registry (ELTR), years 2000-2022, were compared.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NASH/MASH also increased: SRTR 9%-28%, ELTR 5%-12%. From SRTR, NASH/MASH was the common etiology by 2022;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ALD and NASH/MASH are now leading indications for liver transplantation in 2 large global regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver transplantation: MASH share of the US waitlist for steatotic liver disease, 2010 to 2023
“Steatotic liver disease (SLD) is the leading indication for liver transplantation (LT) among U.S. adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 65,675 adults on the LT waitlist secondary to SLD (median age 57 years old [IQR 50–64], 65.1% men, 74.9% NHW, 3.2% AA, 17.9% Hispanic, 2.5% API, 1.1% AI/AN, and 0.5% multiracial) from 2010 to 2023 (Table 1). Overall, 44.5% had MASH (vs 55.5% ALD) while 17.2% had HCC (vs 82.8% non-HCC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease: risk of fatal and non-fatal events by severity of NAFLD, meta-analysis
“We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease: principal cause of death, American Heart Association scientific statement
Cardiovascular disease: atherosclerosis, heart failure, and arrhythmia
“The most common causes of death in patients with NAFLD overall are cardiovascular disease (CVD) and nonhepatic malignancy, followed by liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A strong association exists between NAFLD and atherosclerotic heart disease, heart failure, and arrhythmias, particularly atrial fibrillation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, in a large prospectively studied observational cohort, the incidence of cardiac events was the same across all fibrosis stages; however, the number of cardiac events was relatively low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic kidney disease: risk of incident CKD, meta-analysis
“We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NAFLD was associated with a moderately increased risk of incident CKD (n=10 studies; random-effects HR 1.43, 95% CI 1.33 to 1.54;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All risks were independent of age, sex, obesity, hypertension, diabetes and other conventional CKD risk factors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chronic kidney disease: higher prevalence with advanced fibrosis
“A meta-analysis of 20 cross-sectional studies (n = 28,000 individuals) found that NAFLD was associated with a 2-fold increased prevalence of CKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recently published data from the NASH CRN demonstrate a higher prevalence of CKD in patients with advanced fibrosis compared with lower fibrosis stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
New-onset nonhepatic outcomes: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2
“New-onset hypertension (7.8 events per 100 person-years) was the most common new nonhepatic outcome, followed by type 2 diabetes (4.8 events per 100 person-years), chronic kidney disease (2.5 events per 100 person-years), cardiac events (0.8 events per 100 person-years), nonhepatic cancer (0.8 events per 100 person-years), and cerebrovascular events (0.4 events per 100 person-years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Extrahepatic cancer: risk of incident extrahepatic cancers, meta-analysis
“We performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NAFLD was significantly associated with a nearly 1.5-fold to twofold increased risk of developing GI cancers (oesophagus, stomach, pancreas or colorectal cancers). Furthermore, NAFLD was associated with an approximately 1.2-fold to 1.5-fold increased risk of developing lung, breast, gynaecological or urinary system cancers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Extrahepatic cancer: leading contributor to excess mortality in biopsy-confirmed NAFLD, Sweden
“This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966–2017; n=10,568).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The excess mortality associated with NAFLD was primarily from extra-hepatic cancer (4.5/1000PY; aHR=2.16, 95%CI=2.03–2.30), followed by cirrhosis (2.7/1000PY; aHR=18.15, 95%CI=14.78–22.30), cardiovascular disease (1.4/1000PY; aHR=1.35, 95%CI=1.26–1.44) and hepatocellular carcinoma (HCC)(1.2/1000PY; aHR=11.12, 95%CI=8.65–14.30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
Humanistic burden and health-related quality of life
SF-36 component scores, anxiety, and depression in 136 US adults with physician-diagnosed NASH versus matched general population and type 2 diabetes cohorts, 2016 National Health and Wellness Survey
“Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States. Respondents with physician-diagnosed NASH, physician-diagnosed T2DM, and respondents from the general population were compared.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NASH cohort did not differ from matched T2DM cohort (N = 272) on mental or work-related WPAI scores, but had significantly worse physical status (PCS 40.52 vs. 44.58, p = 0.001), higher % with anxiety (39.9% vs 27.8%, p = 0.043)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SF-36 physical and mental health by fibrosis stage in 713 adults with NAFLD, NASH Clinical Research Network
“QOL data were collected from adults with NAFLD enrolled in the NASH Clinical Research Network using the SF-36 survey and scores were compared to normative U.S. population scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 713 subjects with NAFLD (M=269, F=444) were included. Mean age of subjects was 48.3 years; 61% had definite NASH, and 28% had bridging fibrosis or cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects with NAFLD had worse physical (mean=45.2) and mental health scores (mean=47.6) compared to the U.S. population with (mean=50) and without (physical: 55.8, mental: 52.5) chronic illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects with cirrhosis had significantly (P<0.001) poorer physical health scores (38.4) vs. subjects with no (47.6), mild (46.2), moderate (44.6) or bridging fibrosis (44.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mental health scores did not differ between participants with and without NASH or by degree of fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical health-related patient-reported outcomes in 72 adults with biopsy-proven NASH and F2 or F3 fibrosis, as summarized in a systematic review
“Biopsy-proven NASH with stage F2/F3 fibrosis (72)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, physical health-related PROs of patients with NASH were lower than established general population levels, regardless of fibrosis stage (F3: p <0.05 for physical functioning, role-physical, general health, and PCS of SF-36; F2: p <0.05 for general health and PCS of SF-36)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Health-related work productivity and activity impairment scores at baseline were significantly greater than 0 (p <0.05 except for absenteeism)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes in 1667 adults with NASH and F3 or F4 fibrosis versus the general population, STELLAR trial baseline
“We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selonsertib (NCT03053050 and NCT03053063) who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean physical health-related PRO scores were significantly lower than those of the general population: patients with F4 fibrosis had score reductions of 4.4% to 12.9% in 6/8 SF-36 domains and patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4/8 domains (P < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In multivariate regression analysis, factors independently associated with lower PRO scores included having cirrhosis, female sex, higher body mass index, history of smoking, and diabetes or other comorbidities (P < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fatigue and pruritus in 1,669 adults with NASH and bridging fibrosis or compensated cirrhosis, STELLAR 3 and 4 baseline
“were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All PRO scores of patients with fatigue were significantly impaired (mean up to −31% of a PRO range size in comparison to patients without fatigue).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All PROs were impaired (by up to −19% of a range size, all P < 0.01) in patients with NASH with pruritus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although patients with bridging fibrosis had higher median fatigue scores (indicative of less fatigue) than those with cirrhosis (5.0 [IQR 4.0‐5.8] vs. 4.7 [3.5‐5.7]; P = 0.0028), the difference does not meet the threshold of a minimal clinically important difference for domain scores of the CLDQ‐NASH (approximately 0.5 points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes and fibrosis improvement in 392 adults with NASH and bridging fibrosis or compensated cirrhosis, phase 2 trial NCT03449446
“Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2, randomized, placebo‐controlled study of selonsertib, firsocostat, or cilofexor, alone or in two‐drug combinations (NCT03449446).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 392 patients with NASH (mean ± SD, 60 ± 9 years old; 35% men; 89% white; 72% diabetes; and 56% compensated cirrhosis) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline Physical Functioning (PF) and Bodily Pain of SF‐36 and Fatigue and Worry of CLDQ‐NASH were significantly lower in patients with cirrhosis (total CLDQ‐NASH score mean ± SD, 4.91 ± 1.06 with cirrhosis vs. 5.16 ± 1.14 without cirrhosis; P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 48 weeks of treatment, patients with ≥1‐stage fibrosis improvement without worsening of NASH experienced improvement in EQ‐5D and five out of six CLDQ‐NASH domains (P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fibrosis regression was independently associated with greater improvements in PF and EQ‐5D scores, while NAS improvement was associated with improvement in fatigue and pruritus (all P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CLDQ-MASH domain scores by histologic fibrosis stage (F3 to F4 versus F0 to F2) in adults with MASH
“There were 4,213 MASH patients included: age 56 ± 11 years, 44% male, 65% type 2 diabetes, 69% advanced fibrosis (F3–F4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After item reduction and exploratory factor analysis with the training set (>90% variance), the CLDQ-MASH contained 35 items and seven domains.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, in the context of liver disease severity, the CLDQ-MASH was able to discriminate individuals with vs. without histologic advanced fibrosis (p <0.05 for three domains and the total score)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CLDQ-NAFLD disease-specific instrument: 36 items in six domains
“Thus, the resulting Chronic Liver Disease Questionnaire-Non-Alcoholic Fatty Liver Disease version instrument had 36 items grouped into six domains: Abdominal Symptoms, Activity, Emotional, Fatigue, Systemic Symptoms, and Worry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The domains' correlations with the most relevant domains of Short Form-36 exceeded 0.70.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D and CLDQ-NAFLD index by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study
“The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain, and the UK) and the USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the patients, 767 (20%) provided information on indirect costs and health-related quality of life using the EuroQOL 5-D (EQ-5D; n = 749) and Chronic Liver Disease Questionnaire – Non-Alcoholic Fatty Liver Disease (CLDQ-NAFLD) (n = 723).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, there was a clear pattern of decreasing HRQoL score with worsening fibrosis score in all countries, with the exception of France, where similar scores were seen in both early and advanced fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average CLDQ-NAFLD index was 4.9, with France having the highest score at 5.7 and the USA having the lowest score of 4.4 (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Index and population, mean (SD) | Early (F0–F2) | Advanced (F3–F4) | Overall |
|---|---|---|---|
| EQ-5D index, United States (n = 58, 36, 94) | “0.80 (0.19)”View highlighted excerpt for this quote | “0.67 (0.23)”View highlighted excerpt for this quote | “0.75 (0.22)”View highlighted excerpt for this quote |
| EQ-5D index, all countries (n = 531, 218, 749) | “0.80 (0.2)”View highlighted excerpt for this quote | “0.62 (0.33)”View highlighted excerpt for this quote | “0.75 (0.26)”View highlighted excerpt for this quote |
| CLDQ-NAFLD index, USA (n = 55, 36, 91) | “4.7 (1.05)”View highlighted excerpt for this quote | “4.0 (1.12)”View highlighted excerpt for this quote | “4.4 (1.12)”View highlighted excerpt for this quote |
| CLDQ-NAFLD index, all countries (n = 513, 210, 723) | “5.2 (1.1)”View highlighted excerpt for this quote | “4.4 (1.4)”View highlighted excerpt for this quote | “4.9 (1.2)”View highlighted excerpt for this quote |
EQ-5D-5L by fibrosis stage and cardiovascular, renal, and metabolic comorbidity in adults with MASH, Canada, France, Germany, and Italy, 2024
“Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were grouped as: early fibrosis (stage 0–2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3–4) with additional CVRM comorbidities (AFwC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean EQ-5D-5L scores were lower for EFwC patients (0.85 ± 0.16 [n = 524]) and AFwC patients (0.81 ± 0.18 [n = 113]) compared with EFnoC patients (0.90 ± 0.12 [n = 48], p <0.05 and p <0.001, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with AFwC experienced greater cognitive and emotional impairment, required professional caregivers more often, and had increased rates of hospitalization compared with those with EFwC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline mapped EQ-5D utility by fibrosis stage in 800 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, ESSENCE trial part 1
“Adults with biopsy-confirmed MASH and fibrosis stage F2 or F3 were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo plus standard of care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 800 participants were included in this analysis (semaglutide 2.4 mg n = 534; placebo n = 266).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“31.3% of participants had stage 2 fibrosis, 68.8% had stage 3 fibrosis, and 55.9% had type 2 diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across the study population, the baseline mapped health utility (∼0.78, Table 1) was lower than that reported in the literature for a similar patient population (0.84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Baseline group | Baseline EQ-5D utility, mean (SD) |
|---|---|
| Fibrosis stage 2, semaglutide (n = 169) | “0.783 (0.186)”View highlighted excerpt for this quote |
| Fibrosis stage 2, placebo (n = 81) | “0.789 (0.190)”View highlighted excerpt for this quote |
| Fibrosis stage 3, semaglutide (n = 365) | “0.792 (0.176)”View highlighted excerpt for this quote |
| Fibrosis stage 3, placebo (n = 185) | “0.769 (0.194)”View highlighted excerpt for this quote |
Pruritus, fatigue, and sleep disorders in 8034 adults with MASLD, Global NAFLD/MASLD Registry
“Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SF-6D health utility in noncirrhotic and cirrhotic NAFLD, 89 outpatients
“There were 89 patients with the spectrum of NAFLD completed the SF-36 questionnaire: 59 with non-cirrhotic NAFLD and 30 with cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NAFLD had significantly lower quality of life and health utility scores than the general population (all p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, patients with cirrhosis had lower quality of life and utility scores than non-cirrhotic NAFLD patients: SF-6D 0.660±0.107 in non-cirrhotic NAFLD vs 0.551±0.138 in cirrhotic NAFLD (p=0.0003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life in NASH: systematic review of 23 studies
“Twenty-five publications covering 23 unique studies were identified. Overall, the data showed a substantial impact of NASH on HRQoL, particularly in terms of physical functioning and fatigue, with deterioration of physical and mental health as NASH progresses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalent symptoms, including fatigue, abdominal pain, anxiety/depression, cognition problems, and poor sleep quality, adversely impact patients’ ability to work and perform activities of daily living and the quality of relationships.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most studies were rated ‘moderate’ at quality assessment, and all evaluable studies had inadequate control of confounders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis stage and quality of life: meta-analysis of 13 cohort studies
“Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three studies examined the effects of increasing fibrosis on quality of life had inconsistent findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further studies are needed to assess the association between fibrosis stage and patient quality of life and establish that change in liver fibrosis stage is a valid endpoint for use in clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Annual direct medical costs of NAFLD in the United States, steady-state prevalence model
“We constructed a steady-state prevalence model to quantify this burden in the United States and Europe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the United States, over 64 million people are projected to have NAFLD, with annual direct medical costs of about $103 billion ($1,613 per patient).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are highest in patients aged 45-65. The burden is significantly higher when societal costs are included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lifetime direct costs of NASH and advanced NASH in US adults, Markov model, 2017
“We constructed lifetime Markov models for all stages of NASH and a separate model to specifically identify the increased burden of advanced NASH (fibrosis stage >3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs included inpatient, outpatient, professional services, emergency department, and drug costs, which were obtained from the Center for Medicare and Medicaid Services Fee Schedule 2017 and published data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lifetime costs of all NASH patients in the United States in 2017 will be $222.6 billion, and the cost of the advanced NASH population will be $95.4 billion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct medical and indirect costs by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study, 2018
“In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For 2018, the mean total annual per patient cost of NASH was €2,763, €4,917, and €5,509 for direct medical, direct non-medical, and indirect costs, respectively. National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation, driven by hospitalisation and comorbidities. Indirect costs were driven by work loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, costs for patients with advanced fibrosis were higher (€3,983) than for those with early-stage fibrosis (€2,224).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A major share of indirect costs resulted from early retirement or stopping working (74%), followed by time off work in the previous 12 months (26%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patient indirect or productivity-related costs correlated positively with NASH severity, because patients with relatively more severe disease had to stop working (12% vs. 5% in patients with early-stage disease) or cited that their retirement was the result of NASH (13% vs. 5% in patients with early-stage disease)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Mean annual cost per patient (SD) | Early fibrosis | Advanced fibrosis | USA |
|---|---|---|---|
| NASH-related direct medical (physician-reported, n = 2,604, 1,150, 1,221) | “€2,224 (19,956)”View highlighted excerpt for this quote | “€3,983 (23,788)”View highlighted excerpt for this quote | “€4,881 (42,077)”View highlighted excerpt for this quote |
| Total direct medical, NASH-related and non-NASH | “€3,883 (20,634)”View highlighted excerpt for this quote | “€6,727 (25,052)”View highlighted excerpt for this quote | “€7,258 (36,704)”View highlighted excerpt for this quote |
| Indirect (patient-reported, n = 546, 221, 97) | “€5,939 (15,989)”View highlighted excerpt for this quote | “€12,642 (21,813)”View highlighted excerpt for this quote | “€13,435 (29,493)”View highlighted excerpt for this quote |
Annual non-drug costs by fibrosis stage and liver health state in a US cost-effectiveness model, based on US estimates from the GAIN study
| Health state | Annual cost, base case | Lower value | Upper value |
|---|---|---|---|
| F0 to F2 | “$7,063” | “$5,650” | “$8,475” |
| F3 | “$8,423” | “$6,738” | “$10,108” |
| Compensated cirrhosis | “$34,275” | “$27,420” | “$41,131” |
| Decompensated cirrhosis | “$158,480” | “$126,784” | “$190,176” |
| Hepatocellular carcinoma | “$115,002” | “$92,001” | “$138,002” |
Annual direct medical cost by liver health state, 2025 US dollars, payer-perspective model funded by a diagnostics manufacturer
“Our study was conducted from a health-care payer perspective and included direct medical costs associated with each health state (Table 2), including inpatient and outpatient, medications, and procedures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were sourced from published literature using a combination of micro-costing and gross-costing methods, adjusted using the Consumer Price Index, and reported in 2025 United States dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Health state | Direct medical cost, 2025 USD per year, base value | Range |
|---|---|---|
| F0-1 | “500”View highlighted excerpt for this quote | “480–510”View highlighted excerpt for this quote |
| F2-3 | “1180”View highlighted excerpt for this quote | “640–1720”View highlighted excerpt for this quote |
| Compensated cirrhosis | “23,360”View highlighted excerpt for this quote | “18,210–28,510”View highlighted excerpt for this quote |
| Decompensated cirrhosis | “36,290”View highlighted excerpt for this quote | “30,190–42,390”View highlighted excerpt for this quote |
| Hepatocellular carcinoma | “85,840”View highlighted excerpt for this quote | “60,900–110,790”View highlighted excerpt for this quote |
All-cause annual costs by FIB-4 category in 6,743 US adults with NASH, linked electronic health record and claims data, 2016 to 2020
“Adults with NASH were identified in the Veradigm Health Insights Electronic Health Record Database and linked Komodo claims data. The index date was the earliest coded NASH diagnosis between 1 January 2016 and 31 December 2020 with valid FIB-4 and ≥6 months of database activity and continuous enrollment pre- and post-index.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 6,743 qualifying patients, index FIB-4 was ≤0.95 for 2,345 patents, 0.95-2.67 for 3,289 patients, 2.67-4.12 for 571 patients, and >4.12 for 538 patients (mean age 55.8 years; 62.9% female).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean age, comorbidity burden, cardiovascular disease risk, and healthcare utilization increased with increasing FIB-4. Mean ± SD annual costs increased from $16,744±$53,810 to $34,667±$67,691 between the lowest and highest FIB-4 cohorts” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A one-unit increase in FIB-4 at index was associated with a 3.4% (95%CI: 1.7%-5.2%) increase in mean total annual cost and an 11.6% (95%CI: 8.0%-15.3%) increased likelihood of hospitalization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health care costs after identification of FIB-4-defined F3 or F4 fibrosis in 251,725 commercially insured US adults with NAFLD or NASH, 2008 to 2016
“Using the Optum Research Database, a retrospective cohort study was conducted among 251,725 commercially insured adult patients with ≥1 NAFLD/NASH diagnosis from January 1, 2008, to August 31, 2016, and laboratory data required to calculate FIB‐4 scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of FIB‐4‐based F3 and F4 fibrosis was 0.40%‐2.72% and 1.03%‐1.61%, respectively. Almost 50% of patients identified with FIB‐4‐based F3 or F4 had type 2 diabetes, cardiovascular disease, or renal impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total all‐cause health care costs increased significantly from pre‐index to post‐index for patients with FIB‐4‐based F3 fibrosis across most criteria (17%‐29% increase) and patients with FIB‐4‐based F4 fibrosis across all criteria (47%‐48% increase). Inpatient costs were the primary drivers of this increment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual all-cause costs by advanced liver disease stage in 485,774 commercially insured US adults with NAFLD or NASH, 2016 US dollars
“Adult NAFLD/NASH patients were identified retrospectively from MarketScan Commercial claims (2006-2016). Following initial NAFLD/NASH diagnosis, advanced liver diseases were identified using the first diagnosis as their index date. Mean annual all-cause HRU and costs (2016 USD) were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the database, 485,774 NAFLD/NASH patients met eligibility criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with NAFLD/NASH without advanced liver diseases (adjusted costs: $23,860), the annual cost of CC, DCC, LT, and HCC were 1.22, 5.64, 8.27, and 4.09 times higher [adjusted costs: $29,078, $134,448, $197,392, and $97,563 (P<0.0001)]. Inpatient admissions significantly drove increasing HRU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inpatient and outpatient charges and payments in Medicare beneficiaries with NAFLD, with and without cirrhosis, 2010
“Medicare beneficiaries (January 1, 2010 to December 31, 2010) with NAFLD diagnosis by International Classification of Diseases, Ninth Revision codes in the absence of other liver diseases were selected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 976 inpatients and 4742 outpatients with NAFLD were included—87% were white, 36% male, 30% had cardiovascular disease (CVD) or metabolic syndrome conditions, and 12% had cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For inpatients, median total hospital charge was $36,289. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($61,151 vs. $33,863 and $18,804 vs. $10,146, P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For outpatients, median total charge was $9,011. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($12,049 vs. $8,830 and $2,586 vs. $1,734, P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource use and work impairment in 136 US adults with NASH versus matched general population, 2016 National Health and Wellness Survey
“Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of HRU, there were more visits to an HCP (8.43 vs. 5.17, p < 0.001), ER visits (0.73 vs. 0.38, p = 0.021), and hospitalizations (0.43 vs. 0.21, p = 0.024) for NASH compared to the matched general population cohort (Fig. 3) and NASH patients reported more specialty visits (p’s < 0.05), for example, more general/family medicine provider visits (1.49 vs. 1.14, p = 0.040), hepatologist visits (0.10 vs. 0.02, p = 0.022), and gastroenterologist visits (0.38 vs. 0.12 p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Impairment of work and activity on WPAI was significantly higher for NASH patients compared to matched general population cohort, including absenteeism (17.0% vs. 9.2%, p = 0.041) and presenteeism (32.9% vs. 22.2%, p = 0.019), as well as overall work impairment (39.6% vs. 26.2%, p = 0.011), and activity impairment (44.7% vs. 30.8%, p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and activity impairment by fibrosis risk category in 429 US adults with MASH, 2019 and 2022 physician and patient surveys
“We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 87 physicians and 429 individuals with MASH provided data. The impact of MASH on activities was greater in high-versus low-risk MASH (activity impairment score: high risk, 30.8%; low risk, 17%; p <0.001 across all risk categories). Overall work impairment scores were 18.8% in low-risk and 19.9% in high-risk MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis was funded by Eli Lilly and Company.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization and work impairment by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024
“Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AFwC patients also experienced greater impairment while working compared with EFnoC patients (29.7 ± 26.5 [n = 35] vs. 16.1 ± 21.3 [n = 28], p = 0.0271).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, the overall hospitalization rate was low in the 12 months before data collection (mean: 0.1 ± 1.1 times). However, those with AFwC were significantly more likely to be hospitalized because MASH comorbidities compared with those with EFnoC (p <0.0001; Table S7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled US health care costs averted by a hypothetical therapy halting fibrosis progression in MASLD with moderate to advanced fibrosis
“The US MASLD disease burden model is a Markov model which forecasts disease progression and the impact of diagnosis and treatment. Diagnostic costs for all patients and direct costs for patients with MASLD-related liver disease were also incorporated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis on families
Informal and professional caregiver costs by fibrosis stage in adults with NASH, United States and five European countries, GAIN study
“The secondary objective was to estimate the total annualised cost of the disease, including all health-related items and non-health and indirect costs accrued by patients and their families.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall direct non-medical cost per patient was €4,917 (Table 5). Professional (34%) and informal (48%) caregivers accounted for most of these costs and these percentages increased with disease severity (fibrosis stage).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers, whether professional or informal, accounted for the greatest proportion of direct non-medical costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The remaining direct non-medical costs resulted from transport, disability allowances, alternative therapies, home alteration, and OTC remedies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Mean annual direct non-medical cost per patient (SD), patient-reported | Early fibrosis (n = 546) | Advanced fibrosis (n = 221) | USA (n = 97) |
|---|---|---|---|
| Non-medical | “€1,704 (5,785)”View highlighted excerpt for this quote | “€4,661 (9,839)”View highlighted excerpt for this quote | “€3,243 (7,685)”View highlighted excerpt for this quote |
Economic impact of diagnostic testing
Fibrosis staging required for coverage of resmetirom or semaglutide: liver biopsy, VCTE, MRE, or ELF test, national commercial prior authorization policy
Unit costs of the ELF test, transient elastography, imaging, and liver biopsy in hepatology workup, 2025 US dollars, model funded by a diagnostics manufacturer
“Hepatology workup costs comprised of specialist consultation and fibrosis staging, which reflected standard practice using a combination of liver biopsy, ELF, and imaging-based modalities (TE, MRE, or liver ultrasound). Resource use frequencies for each staging component were estimated from the same real-world cohort and are reported in Table 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were sourced from published literature using a combination of micro-costing and gross-costing methods, adjusted using the Consumer Price Index, and reported in 2025 United States dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Test or service, 2025 USD | Cost | Resource use in hepatology workup |
|---|---|---|
| ELF test, one-time screening cost (range) | “200”View highlighted excerpt for this quote( “170–230”View highlighted excerpt for this quote) | Not applicable |
| FIB-4 test, one-time screening cost | “0”View highlighted excerpt for this quote | Not applicable |
| Hepatology consultation | “257”View highlighted excerpt for this quote | “100”View highlighted excerpt for this quote |
| ELF test in hepatology workup | “185”View highlighted excerpt for this quote | “25”View highlighted excerpt for this quote |
| Transient elastography | “32”View highlighted excerpt for this quote | “25”View highlighted excerpt for this quote |
| Ultrasound liver | “136”View highlighted excerpt for this quote | “200”View highlighted excerpt for this quote |
| MRI or CT abdomen or liver | “323”View highlighted excerpt for this quote | “5”View highlighted excerpt for this quote |
| Liver biopsy | “354”View highlighted excerpt for this quote | “15”View highlighted excerpt for this quote |
Lifetime costs of FIB-4 and ELF screening strategies with resmetirom treatment of F2 to F3 fibrosis in high-risk US primary care patients, model funded by a diagnostics manufacturer
“We developed a decision-analytic model for MASLD natural history and treatment to compare 6 noninvasive test strategies using Fibrosis-4 (FIB-4) and/or enhanced liver fibrosis (ELF) tests at varying cutoffs. Patients identified with significant fibrosis were referred for hepatology staging (biopsy and/or imaging-based), and eligible individuals were considered for Resmetirom ($47,400/y; mean duration: 1.6–1.8 year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sequential screening with ELF (cutoff 9.80) following indeterminate FIB-4 (1.3–2.67) was the most cost-effective, yielding 8.610 QALYs and $96,990 in lifetime costs at a $100,000/QALY threshold. ELF-alone screening at a 9.00 cutoff maximized QALYs and individuals treated but increased unnecessary referrals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Resmetirom treatment costs were obtained from Centers for Medicare & Medicaid Services ($47,400/y at the time of analysis) and applied exclusively to individuals with F2-3 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs of FIB-4 followed by VCTE or ELF screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis
“Six screening strategies were assessed, using either vibration-controlled transient elastography (VCTE) or the enhanced liver fibrosis (ELF) test as a second-line test following an initial Fibrosis-4 (FIB-4) assessment as the first line NIT. The model included treatment effects of resmetirom for metabolic dysfunction-associated steatohepatitis (MASH) patients with F2 or F3 fibrosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All screening strategies for high-risk MASLD in US incurred additional costs compared to no screening, ranging from $13 587 to $14 730 per patient with T2D and $14 274 to $15 661 per patient with obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ICERs ranged from $26 913 to $27 884 per QALY for T2D patients and $23 265 to $24 992 per QALY for patients with obesity. While ICERs were influenced by VCTE availability, they remained cost-effective when using ELF as the second-line test.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Five-year direct costs of FIB-4 followed by ELF or VCTE screening of all US adults living with diabetes, 2026 to 2030, study funded by test and drug manufacturers
“This study aimed to estimate the direct healthcare costs of two MASLD and MASH screening strategies among all people living with diabetes in Brazil, Germany, Japan, the Kingdom of Saudi Arabia (KSA), Spain and the United States (US), from 2026 to 2030.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Fibrosis‐4 (FIB‐4) index was used as the first line test, followed by the Enhanced Liver Fibrosis (ELF) test or vibration‐controlled transient elastography (VCTE) for confirmatory assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 5 years, the estimated costs of Strategy 1 ranged from R$0.7–1.3 billion for Brazil, €346–617 million for Germany, ¥80–172 billion for Japan, SAR 3.7–6.0 billion for the KSA, €591–949 million for Spain and $2.7–15.2 billion for the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strategy 2 resulted in higher costs, ranging from R$1.2–2.0 billion for Brazil, €528–940 million for Germany, ¥121–262 billion for Japan, SAR 5.7–9.2 billion for the KSA, €0.9–1.4 billion for Spain and $4.1–23 billion for the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Boehringer Ingelheim, Echosens and Novo Nordisk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of VCTE examinations needed under the current FIB-4-based algorithm for 75.8 million US adults with MASLD, NHANES 2017 to 2020
“Current guidelines recommend using the Fibrosis-4 score for initial identification of subjects at risk of future complications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We interrogated the National Health and Nutrition Examination Survey data, 2017–20, in which a sample of subjects representative of US civilian population underwent vibration-controlled transient elastography (VCTE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the survey data, 2,691 subjects, projecting to 75.8 million US adults, were found to have MASLD, of whom 11% had LSM 8–12 kPa and 6% LSM ≥12 kPa. When the current guideline was applied, 18.1 million VCTEs would be needed to diagnose 3.5 million subjects with LSM ≥8 kPa and 1.7 million subjects with LSM ≥12 kPa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“would detect 4.9 million with LSM ≥8 kPa and 2.5 million subjects with LSM ≥12 kPa (37% and 45% improvement over the current guideline, respectively), while requiring 5.0 million fewer VCTEs (28% reduction).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Confirmatory fibrosis testing needed after FIB-4 screening of 8,366 US primary care patients with type 2 diabetes or prediabetes, 2022 to 2024
“This cross-sectional study evaluated primary care patients with T2DM or prediabetes and a FIB-4 score between 2022 and 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 8,366 patients with T2DM and prediabetes, 2,064 (25%) had FIB-4s in need of confirmatory risk assessment. The expanded FIB-4 fibrosis screening for T2DM and prediabetes increased the number of patients needing confirmatory fibrosis risk assessment by 9.1 times compared to those with diagnoses of MASLD (n=228).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expanded screening for advanced liver fibrosis would substantially increase the number of patients who need confirmatory testing for liver fibrosis, increasing cost and straining access.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, we only included patients from a single academic healthcare system in the southeastern United States” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Use of liver biopsy and transient elastography in US and European NASH practice, GAIN study
“Key differences in practice between the EU5 countries and USA were that imaging techniques were less frequently used in the USA: 618 (51%) patients received an ultrasound compared with an average of 76% in EU5 countries; and only a minority received transient elastography: 157 (13%) compared with a total of 1,071 (42%) in EU5 countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The reported rate of liver biopsy was lowest in Spain (130 patients, 25%), and highest in the USA (697, 57%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For instance, in the USA, the main sources of data were the Medicaid National Average Drug Acquisition Cost database for drug costs, the Centre for Medicare and Medicaid services for test procedures and surgeries, and the American Medical Association for consultations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of diagnostic tests and biopsy confirmation rate by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024
“Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, only 22.9% (n = 532/2,319) of patients had their MASH diagnosis confirmed by liver biopsy. Non-invasive diagnostic techniques were reported for 97.3% of patients (n = 2,513/2,584).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To diagnose MASH, a mean of 19.6 ± 11.29 tests were conducted in total. The most common test type was comorbidity assessments (5.5 ± 4.1). On average, significantly more diagnostic tests were required for patients with EFwC (19.7 ± 11.3, p = 0.0054) and AFwC (23.8 ± 11.9, p <0.0001) compared with those with EFnoC (17.4 ± 10.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, patients with AFwC required significantly more imaging scans to monitor MASH in the 2 years before data collection compared with those with EFnoC (p <0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Lifestyle intervention and weight loss
EASL-EASD-EASO guideline recommendations: weight loss targets, diet quality, and physical activity in adults with MASLD
EASL-EASD-EASO guideline: achievement and maintenance of weight loss
AASLD practice guidance statements: caloric deficit and physical activity
“Thus, actionable statements rather than formal recommendations are provided herein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NAFLD who are overweight or obese should be prescribed a diet that leads to a caloric deficit. When possible, diets with limited carbohydrates and saturated fat and enriched with high fiber and unsaturated fats (eg, Mediterranean diet) should be encouraged due to their additional cardiovascular benefits” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NAFLD should be strongly encouraged to increase their activity level to the extent possible. Individualized prescriptive exercise recommendations may increase sustainability and have benefits independent of weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASLD practice guidance: magnitude of weight loss and its maintenance
“Weight loss of 3%–5% improves steatosis, but greater weight loss (> 10%) is generally required to improve NASH and fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Few patients (≤ 10%) achieve effective weight loss despite structured interventions at 1 year, and fewer than half of these maintain the weight lost 5 years after intervention” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight loss improves hepatic steatosis, NASH, and hepatic fibrosis in a dose-dependent manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ADA Standards of Care recommendation 4.25: lifestyle change in adults with type 2 diabetes or prediabetes and MASLD
“Adults with type 2 diabetes or prediabetes, particularly with overweight or obesity, who have metabolic dysfunction–associated steatotic liver disease (MASLD) should be recommended lifestyle changes using an interprofessional approach that promotes weight loss, ideally within a structured nutrition plan and physical activity program for cardiometabolic benefits B and histological improvement. C” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is consensus that a minimum weight loss goal of 5%, preferably ≥10%, is needed to improve liver histology” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individualized, structured weight loss and exercise programs offer greater benefit than standard counseling in people with MASLD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASLD updates on resmetirom and semaglutide: lifestyle modification alongside pharmacotherapy
Weight loss and histology in biopsy-proven NASH: prospective cohort in Havana, Cuba, 293 participants, 261 with paired biopsies at week 52
“We conducted a prospective study of 293 patients with histologically proven NASH who were encouraged to adopt recommended lifestyle changes to reduce their weight over 52 weeks, from June 2009 through May 2013, at a tertiary medical center in Havana, Cuba.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Paired liver biopsies were available from 261 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week fifty-two, 88 subjects (30%) had lost ≥5% of their weight.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients who lost ≥10% of their weight had reductions NAS, 90% had resolution of NASH, and 45% had regression of fibrosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intensive lifestyle intervention: randomized trial in 31 overweight or obese adults with biopsy-proven NASH, 48 weeks
“Thirty one overweight or obese individuals (Body mass index 25-40 kg/m2) with biopsy proven NASH were randomized in a 2:1 ratio to receive intensive lifestyle intervention (LS) or structured education (control).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 48 weeks of intervention, participants assigned to LS lost an average of 9.3% of their weight vs 0.2% in the control group (p=0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A higher proportion of participants in the LS group had a reduction of NAS ≥ 3 points or had post treatment NAS ≤ 2 as compared to the control group (72% vs 30%, p=0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post intervention liver biopsy was completed in 28/31 (90%) of participants, 18/21 (86%) in the lifestyle intervention group and 10/10 (100%) in the control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thyroid hormone receptor-beta agonists
FDA-approved indication and dosage: resmetirom
MAESTRO-NASH week 52 primary end points: 966-patient primary analysis population
EASL-EASD-EASO guideline recommendations: resmetirom in non-cirrhotic MASH with significant fibrosis
EASL-EASD-EASO guideline: response rates, duration of therapy, and use with GLP-1 receptor agonists
AASLD update to the practice guidance: resmetirom patient selection and exclusions
AASLD update to the practice guidance: continuation or discontinuation of resmetirom at 12 months
AASLD update to the practice guidance: resmetirom in persons already receiving other therapies with potential MASH benefit
ADA Standards of Care recommendation 4.28: referral for thyroid hormone receptor-β agonist treatment in adults with type 2 diabetes or prediabetes
“For consideration of treatment with a thyroid hormone receptor-β agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) liver fibrosis on liver histology, or by a validated imaging-based or blood-based test, refer to a gastroenterologist or hepatologist with expertise in MASLD management. A” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given complexities associated with selection of an individual for therapy, drug cost, and treatment monitoring, therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incretin-based therapies
FDA-approved indication and dosage: semaglutide 2.4 mg injection for noncirrhotic MASH
ESSENCE part 1 primary end points: planned interim analysis of the first 800 patients at week 72
AASLD update to the practice guidance on semaglutide: indication, patient selection, and cirrhosis
AASLD update to the practice guidance on semaglutide: combination with resmetirom
ADA Standards of Care recommendations 4.26 and 4.27a: GLP-1 RA and dual GIP and GLP-1 RA in adults with type 2 diabetes and MASLD
“In adults with type 2 diabetes, MASLD, and overweight or obesity, consider using a glucagon-like peptide 1 receptor agonist (GLP-1 RA) with demonstrated benefits in MASH A or a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA with potential benefits in MASH B for the treatment of obesity as an adjunctive therapy to lifestyle interventions for weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Semaglutide is currently the only glucose-lowering or obesity medication that is FDA approved for the treatment of MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EASL-EASD-EASO guideline recommendations on GLP-1 receptor agonists, issued while the semaglutide phase 3 trial was ongoing
AASLD practice guidance statement on semaglutide for its approved indications, issued before any GLP-1 RA was approved for NASH
“Although several GLP-1RAs are approved for treatment of T2DM, none has been approved for treatment of NASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Semaglutide can be considered for its approved indications (T2DM/obesity) in patients with NASH as it confers a cardiovascular benefit and improves NASH” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: SYNERGY-NASH phase 2 trial in MASH with F2 or F3 fibrosis, 190 randomized participants with missing week 52 biopsies imputed
“We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pioglitazone and vitamin E
AASLD practice guidance statements: pioglitazone and vitamin E
“Pioglitazone improves NASH and can be considered for patients with NASH in the context of patients with T2DM” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vitamin E can be considered in select individuals as it improves NASH in some patients without diabetes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Available data on semaglutide, pioglitazone, and vitamin E do not demonstrate an antifibrotic benefit, and these compounds have not been carefully studied in patients with cirrhosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASLD update to the practice guidance on resmetirom: regulatory status of pioglitazone and vitamin E for MASH
EASL-EASD-EASO guideline recommendations: pioglitazone and vitamin E not recommended as MASH-targeted therapies
ADA Standards of Care recommendations 4.27a, 4.27b, and 4.30a: pioglitazone in adults with type 2 diabetes and MASH
“In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combination therapy with pioglitazone plus GLP-1 RA can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) because of potential beneficial effects on MASH. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the context of treating hyperglycemia in individuals with type 2 diabetes with MASLD, where the low cost of pioglitazone and any liver improvement would be an added benefit to glycemic management, these plans would be potentially cost-effective for the treatment of MASLD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ADA Standards of Care: vitamin E with and without type 2 diabetes
“Vitamin E may be beneficial for the treatment of MASH in individuals without diabetes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, in individuals with type 2 diabetes, vitamin E monotherapy was found to be ineffective in a small RCT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PIVENS: pioglitazone 30 mg or vitamin E 800 IU vs placebo in 247 adults without diabetes, 96 weeks, intention-to-treat primary analysis
“We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis was an intention-to-treat analysis in which the proportions of subjects in each active-treatment group (pioglitazone and vitamin E) in whom there was improvement in nonalcoholic steatohepatitis were compared with the proportion of subjects in the placebo group in whom there was improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P = 0.001), but the difference in the rate of improvement with pioglitazone as compared with placebo was not significant (34% and 19%, respectively; P = 0.04).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“both agents were associated with reductions in hepatic steatosis (P = 0.005 for vitamin E and P<0.001 for pioglitazone) and lobular inflammation (P = 0.02 for vitamin E and P = 0.004 for pioglitazone) but not with improvement in fibrosis scores (P = 0.24 for vitamin E and P = 0.12 for pioglitazone).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PIVENS: resolution of steatohepatitis with pioglitazone, as summarized in the AASLD practice guidance
“In the PIVENS trial, pioglitazone treatment did not meet the a priori primary endpoint of a ≥2-point reduction NAS without worsening of fibrosis, although 47% had NASH resolution compared with 21% of participants receiving placebo (p <0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pioglitazone 45 mg/d for 18 months in 101 randomized participants with NASH and prediabetes or type 2 diabetes
“Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single-center study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pioglitazone safety: weight gain, heart failure, fractures, and bladder cancer in guideline texts
“Potential side effects associated with pioglitazone include weight gain, osteoporosis in postmenopausal women, a debated risk of bladder cancer, and potential risk for worsening heart failure in those with preexisting cardiac dysfunction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“its use in clinical practice has been overtaken by the increasing use of newer antidiabetic agents such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium glucose cotransporter-2 (SGLT-2) inhibitors (SGLT-2i) with pleiotropic metabolic benefits, most notably weight loss and reduction in cardiovascular mortality” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pioglitazone causes dose-dependent weight gain (15 mg/day, mean weight gain of 1–2%; 45 mg/day, mean weight gain of 3–5%), which can be blunted or reversed if combined with SGLT2 inhibitors or GLP-1 RAs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pioglitazone increases fracture risk, may promote heart failure if used in individuals with preexisting congestive heart failure, and may increase the risk of bladder cancer, although this remains controversial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pioglitazone safety: boxed warning for congestive heart failure in the FDA label
Pioglitazone safety in PIVENS: weight gain at week 96 and cardiovascular events
“There was a significant improvement in insulin resistance only in the pioglitazone group, but that group was also the only group that had a significant mean weight gain (a mean increase of 4.7 kg at week 96, P<0.001 for the comparison with placebo)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A similar number of cardiovascular events occurred among subjects taking placebo (12 events), those taking vitamin E (12), and those taking pioglitazone (10). No cases of congestive heart failure were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vitamin E safety and advanced fibrosis outcomes in the AASLD practice guidance
“Although no study has demonstrated that vitamin E meaningfully reduces fibrosis, a retrospective study of 236 patients with NASH and advanced fibrosis showed that vitamin E use was associated with lower rates of hepatic decompensation (37% vs. 62%, p = 0.04) and higher transplant free survival (78% vs. 49%, p < 0.01)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Concern about the risks of vitamin E on bleeding and specifically hemorrhagic stroke has been raised, but prospective data are needed to confirm this observation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, data demonstrating a relationship between vitamin E and prostate cancer are conflicting” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Such potential risks should be discussed with patients before initiation of long-term high-dose (eg, 800 IU daily) vitamin E therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sodium-glucose cotransporter-2 inhibitors and other off-label therapies
EASL-EASD-EASO recommendation on SGLT2 inhibitors and metformin as MASH-targeted therapy
EASL-EASD-EASO statement on statins, fibrates, ezetimibe, and silymarin as MASH treatment
ADA Standards of Care 2026: glucose-lowering therapies other than pioglitazone and GLP-1 RAs in adults with type 2 diabetes and MASLD
“In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“reduce hepatic steatosis, but their effects on steatohepatitis remain unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, these agents have either failed to improve steatohepatitis in paired-biopsy studies (metformin) or have no RCTs with liver histological end points (i.e., sulfonylureas, glitinides, dipeptidyl peptidase 4 inhibitors, or acarbose).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASLD 2023 practice guidance on SGLT2 inhibitors, metformin, ursodeoxycholic acid, DPP-4 inhibitors, statins, and silymarin
“Available studies evaluating the role of SGLT-2i in the treatment of NAFLD/NASH are limited by relatively small sample sizes and lack of histological outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within these limitations, available data suggest SGLT-2i improve hepatic steatosis; however, the therapeutic impact of SGLT-2i on liver histology needs to be better defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Metformin, ursodeoxycholic acid, dipeptidylpeptidase-4, statins, and silymarin are well studied in NASH and should not be used as a treatment for NASH as they do not offer a meaningful histological benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dapagliflozin phase 3 trial (DEAN): design, population, and setting
“Multicentre, double blind, randomised, placebo controlled trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six tertiary hospitals in China from 23 November 2018 to 28 March 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“154 adults with biopsy diagnosed MASH, with or without type 2 diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants were randomly assigned to receive 10 mg orally of dapagliflozin or matching placebo once daily for 48 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 33% participants (51/154) had stage F1 fibrosis, 45% (70/154) had stage F2, and 19% (29/154) had stage F3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dapagliflozin phase 3 trial (DEAN): histologic results at 48 weeks, intention-to-treat analysis
“Analyses used the intention-to-treat dataset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MASH improvement without worsening of fibrosis was reported in 53% (41/78) of participants in the dapagliflozin group and 30% (23/76) in the placebo group (risk ratio 1.73 (95% confidence interval (CI) 1.16 to 2.58); P=0.006).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MASH resolution without worsening of fibrosis occurred in 23% (18/78) of participants in the dapagliflozin group and 8% (6/76) in the placebo group (risk ratio 2.91 (95% CI 1.22 to 6.97); P=0.01). Fibrosis improvement without worsening of MASH was reported in 45% (35/78) of participants in the dapagliflozin group, as compared with 20% (15/76) in the placebo group (risk ratio 2.25 (95% CI 1.35 to 3.75); P=0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dapagliflozin phase 3 trial (DEAN): limitations stated by the authors
“Firstly, our primary endpoint was MASH improvement without worsening of liver fibrosis instead of MASH resolution without worsening of fibrosis or fibrosis improvement without worsening of MASH according to the guidance of FDA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondly, the current trial was conducted in a Chinese population, which limits the broader generalisability of the conclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, because of the scarcity of major adverse liver outcomes (eg, cirrhosis and hepatocellular carcinoma), large scale and long term trials are needed to further confirm these effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bariatric and metabolic surgery
AASLD 2023 practice guidance on bariatric surgery
“Bariatric surgery should be considered as a therapeutic option in patients who meet criteria for metabolic weight loss surgery, as it effectively resolves NAFLD or NASH in the majority of patients without cirrhosis and reduces mortality from CVD and malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The type, safety, and efficacy of bariatric surgery in patients with well-compensated NASH cirrhosis is not established and requires a careful benefit–risk assessment by a multidisciplinary team of experts that includes a hepatologist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Failure to achieve substantial weight loss following bariatric surgery is associated with persistent NASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EASL-EASD-EASO recommendation on bariatric surgery in non-cirrhotic MASLD
ADA Standards of Care 2026: metabolic surgery in adults with type 2 diabetes and MASH
“Consider metabolic surgery in appropriate candidates as an option to treat MASH in adults with type 2 diabetes and obesity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses report that 70–80% of people have improvement in hepatic steatosis, 50–75% of people have improvement in inflammation and hepatocyte ballooning (necrosis), and 30–40% of people have improvement in fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to note that currently metabolic surgery is not indicated solely for treatment of MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BRAVES randomized trial: Roux-en-Y gastric bypass or sleeve gastrectomy vs lifestyle modification plus best medical care, 1-year histology
“We did a multicentre, open-label, randomised trial at three major hospitals in Rome, Italy. We included participants aged 25-70 years with obesity (BMI 30-55 kg/m2), with or without type 2 diabetes, with histologically confirmed NASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint of the study was histological resolution of NASH without worsening of fibrosis at 1-year follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the intention-to-treat analysis, the percentage of participants who met the primary endpoint was significantly higher in the Roux-en-Y gastric bypass group (54 [56%]) and sleeve gastrectomy group (55 [57%]) compared with lifestyle modification (15 [16%]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Severe adverse events occurred in ten (6%) participants who had bariatric-metabolic surgery, but these participants did not require re-operations and severe adverse events were resolved with medical or endoscopic management.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
BRAVES randomized trial: fibrosis improvement at 1 year and fibrosis stage of participants
Prospective cohort of 180 adults with severe obesity and biopsy-proven NASH: histology 5 years after bariatric surgery
“We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SPLENDOR cohort: major adverse liver outcomes and cardiovascular events at 10 years after bariatric surgery in fibrotic NASH without cirrhosis
“In this retrospective cohort study of 1158 patients (including 650 patients who underwent bariatric surgery and 508 patients in the nonsurgical control group) with biopsy-proven fibrotic nonalcoholic steatohepatitis without cirrhosis, bariatric surgery was significantly associated with a lower risk of major adverse liver outcomes (adjusted absolute 10-year risk difference of 12.4%) and major adverse cardiovascular events (adjusted absolute 10-year risk difference of 13.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the patients analyzed with overlap weighting methods, the cumulative incidence of major adverse liver outcomes at 10 years was 2.3% (95% CI, 0%-4.6%) in the bariatric surgery group and 9.6% (95% CI, 6.1%-12.9%) in the nonsurgical group (adjusted absolute risk difference, 12.4% [95% CI, 5.7%-19.7%]; adjusted hazard ratio, 0.12 [95% CI, 0.02-0.63]; P = .01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the first year after bariatric surgery, 4 patients (0.6%) died from surgical complications, including gastrointestinal leak (n = 2) and respiratory failure (n = 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Resmetirom and semaglutide 2.4 mg are approved for noncirrhotic MASH with moderate to advanced liver fibrosis, both under accelerated approval based on improvement of MASH and fibrosis. In the MAESTRO-NASH primary analysis population of 966 patients, NASH resolution with no worsening of fibrosis occurred in 25.9% (resmetirom 80 mg) and 29.9% (100 mg) compared with 9.7% (placebo), and fibrosis improvement by at least one stage in 24.2% and 25.9% compared with 14.2%. The EASL guideline states that evidence is limited to 52-week histological data, that about 70-80 % of participants did not respond according to histological criteria, and that there is no evidence to guide when to stop treatment. In the ESSENCE interim analysis of the first 800 patients at week 72, resolution of steatohepatitis occurred in 62.9% with semaglutide and 34.3% with placebo, and reduction in fibrosis in 36.8% and 22.4%; the AASLD semaglutide update states that 37.1% of treated participants did not resolve MASH and 63.2% did not have a reduction in fibrosis, and that available data do not identify predictors of response. No FDA-approved noninvasive test diagnoses MASH with F2 to F3 or monitors response to pharmacotherapy. Resmetirom and semaglutide have not been studied in combination or compared. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription. The EASL guideline states that agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes and that no MASH-targeted pharmacotherapy can currently be recommended at the cirrhotic stage.
Other options have limits. Few patients (≤ 10%) achieve effective weight loss with structured interventions at 1 year, and fewer than half of these maintain it at 5 years; in one cohort, 88 of 293 participants (30%) lost 5% or more of their weight at week 52. Pioglitazone and vitamin E are not FDA approved for MASH, the EASL guideline does not recommend either as a MASH-targeted therapy, and in a 96-week trial in 247 adults without diabetes neither was associated with improvement in fibrosis scores; pioglitazone was associated with a mean weight gain of 4.7 kg at week 96, and its label states that thiazolidinediones cause or exacerbate congestive heart failure in some patients. The EASL guideline finds insufficient evidence to recommend SGLT2 inhibitors or metformin as MASH-targeted therapies. Metabolic surgery is not indicated solely for treatment of MASH, advanced fibrosis persisted in 47% of individuals in one post-surgery biopsy study, and in a cohort of 650 surgical patients with fibrotic NASH, 4 (0.6%) died from surgical complications within the first year.
Access and persistence are also limited. A diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population has been estimated. In one cohort, 129 of 137 patients prescribed resmetirom (94.2%) required prior authorization, 33 (24.1%) prior authorization denials required appeal, and resmetirom was dispensed on average 22.7 days after prescription; in another cohort, 13 patients (16%) discontinued resmetirom after an average of 25.5 days, 11 because of adverse events. In company market research with 100 US MASH treaters, 85% of specialists described the greatest unmet needs as lack of effective, liver-directed therapies.
Resmetirom: histologic nonresponse, 52-week data, and absence of stopping rules (EASL-EASD-EASO)
Semaglutide: histologic nonresponse at week 72 in ESSENCE and absence of predictors of response (AASLD)
No FDA-approved noninvasive test for selection or monitoring (AASLD)
Unverified clinical benefit of accelerated approvals, untested combinations, and no therapy for MASH cirrhosis (EASL-EASD-EASO research needs)
Combined resmetirom and semaglutide: not studied (AASLD and real-world US cohort)
“Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction-associated steatohepatitis but have not been tested together.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because more than one-third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis rate of the treatment-eligible US population (Madrigal-funded population calculator)
“Published analyses suggest a diagnosis rate of ~ 10% (range 3.3–14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimation of the treatment-eligible population for resmetirom depends importantly on NASH diagnosis rates, which are predicted to be < 15% in the 3 years after drug approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world resmetirom access: prior authorization, denials, and dispensing delays at a US tertiary center
“Among the 137 patients prescribed resmetirom, 129 patients (94.2%) required insurance prior authorization. A total of 33 (24.1%) insurance prior authorization denials were seen, which required an appeal for insurance approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Appeals were denied due to unmet biopsy requirements, expired noninvasive fibrosis testing, or complete plan exclusions. On average, resmetirom was dispensed 22.7 days after being prescribed, with a delay of 12.5 days after insurance approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite insurance approvals, access challenges persisted, with 5 patients discontinuing treatment prematurely due to cost concerns when nonprofit foundation grants were unavailable or logistical issues with specialty pharmacy dispensing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world resmetirom discontinuation in a US hepatology prescription pathway
“Thirteen patients (16%) discontinued resmetirom after an average of 25.5 days (range: 2–68 d), with 11 patients discontinuing due to adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One in 6 patients discontinued resmetirom, primarily due to side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unmet need reported by US MASH treaters (Inventiva market research)
Place in treatment, anticipated use, and care setting
Summary
Lanifibranor is an investigational medicine that has not been approved by any regulatory authority. It is being evaluated in the phase 3 NATiV3 trial in patients with MASH with moderate and advanced fibrosis, and the manufacturer expects to report topline results in the fourth quarter of 2026. In the EASL guideline, management of MASLD consists of lifestyle modification and optimal management of comorbidities, including incretin-based therapies for type 2 diabetes or obesity, with resmetirom, if approved locally, considered as a MASH-targeted therapy for non-cirrhotic MASH with fibrosis stage 2 or higher; no MASH-targeted pharmacotherapy is recommended for the cirrhotic stage. The same guideline describes a phase IIb trial of lanifibranor with dose-dependent histological improvement of steatohepatitis and fibrosis and side effects of a 2.5% increase in weight, pedal oedema, and mild anaemia. For adults with type 2 diabetes and biopsy-proven MASH or high risk of liver fibrosis, the American Diabetes Association prefers a GLP-1 RA for glycemic management, allows pioglitazone plus a GLP-1 RA, and advises referral to a gastroenterologist or hepatologist for consideration of a thyroid hormone receptor-β agonist.
The American Diabetes Association states that MASH therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team, and the Cigna prior authorization policy for Rezdiffra requires prescribing by or in consultation with an endocrinologist, gastroenterologist, or hepatologist. About 14% of MAESTRO-NASH participants were receiving a GLP-1 RA, and the EASL guideline considers it reasonable to use resmetirom by the same criteria in these individuals; the AASLD resmetirom update states that data are insufficient to guide whether or when to start resmetirom in persons already taking therapies with potential MASH efficacy. Combination use of semaglutide 2.4 mg/week with resmetirom has not been studied, and another publication did not recommend upfront combination therapy and supported treatment consideration with resmetirom or semaglutide for noncirrhotic MASLD with liver stiffness of 10 to 20 kPa or ELF of 9.2 to 11.3. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription, mostly before resmetirom (33.8%), and 231 of the remaining 4524 (5.1%) were co-initiators.
The manufacturer describes lanifibranor as a once-daily oral therapy, plans to demonstrate its value as monotherapy and in combination, and states that NATiV3 assesses lanifibranor in combination with GLP-1 and SGLT2 inhibitors. The manufacturer's Form 20-F states that weight gain with lanifibranor may lead patients to prefer a GLP-1 agent for the treatment of MASH.
EASL-EASD-EASO treatment algorithm: lifestyle, comorbidity management, and resmetirom for non-cirrhotic MASH with fibrosis stage 2 or higher
EASL-EASD-EASO guideline on lanifibranor: phase 2b results and ongoing phase 3 trial
ADA Standards of Care 2026: GLP-1 RA, pioglitazone, and THR-β agonist placement in adults with type 2 diabetes and MASH
“In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combination therapy with pioglitazone plus GLP-1 RA can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) because of potential beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For consideration of treatment with a thyroid hormone receptor-β agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) liver fibrosis on liver histology, or by a validated imaging-based or blood-based test, refer to a gastroenterologist or hepatologist with expertise in MASLD management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: specialist initiation of MASH-targeted therapy (ADA Standards of Care 2026)
“Given complexities associated with selection of an individual for therapy, drug cost, and treatment monitoring, therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment initiation and monitoring should be individualized and within the context of an interprofessional team that includes a gastroenterologist or hepatologist, consideration of individual preferences, and a careful shared-decision cost-benefit discussion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: prescriber specialty required by a national formulary prior authorization policy for resmetirom
Resmetirom in patients already receiving a GLP-1 RA (EASL-EASD-EASO)
Sequencing of resmetirom with incretin therapy, pioglitazone, or vitamin E (AASLD October 2024 update)
Combined semaglutide and resmetirom (AASLD November 2025 update)
Updated global consensus 2026: treatment initiation, upfront combination, and selection between resmetirom and semaglutide
“Treatment consideration with resmetirom or semaglutide was supported for noncirrhotic MASLD with liver stiffness measurement values of 10 to 20 kPa or ELF values of 9.2 to 11.3, after exclusion of cirrhosis. Upfront combination therapy with both drugs was not recommended. Selection of pharmacologic therapy was to be determined through shared decision-making between patient and provider and individualized according to the patient's cardiometabolic profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
International expert panel 2026 on resmetirom and semaglutide: individualizing, switching, and combining agents
“The two agents act through complementary mechanisms: resmetirom as a liver-directed thyroid hormone receptor-beta agonist and semaglutide as a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a broad spectrum of metabolic effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We offer practical recommendations for individualising therapy by patient phenotype, managing patients already receiving GLP-1 RAs and defining response, non-response and criteria for switching or combining agents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world incretin exposure and co-initiation among US resmetirom initiators
“Of 6837 initiators, 76.6% had overweight/obesity (code or body mass index [BMI] ≥ 30 kg/m2), 44.0% Type 2 diabetes and 16.8% a cirrhosis code. An incretin prescription was recorded in 37.2%, mostly before resmetirom (33.8%; excluded from the comparison). Of the remaining 4524, 231 (5.1%) were co-initiators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Inventiva positioning: once-daily oral therapy, monotherapy and combination use, and background incretin therapy
Inventiva positioning: combination with GLP-1 RAs and SGLT2 inhibitors in NATiV3 and backbone therapy
Inventiva positioning: patients with or without type 2 diabetes, September 2026
Inventiva risk factors: competition with approved therapies and patient preference for a GLP-1 agent
Heterogeneity of treatment effect
NATIVE: histologic response in participants with type 2 diabetes
NATIVE: race of participants and applicability to other racial and ethnic groups
NATIVE: response by type 2 diabetes status and fibrosis stage F2 to F3 (company presentation)
NATIVE and other phase 2 studies: metabolic response by type 2 diabetes status (descriptive comparison)
NATIVE retrospective analysis: response by PNPLA3 I148M genotype
NATIVE post hoc analysis: response by weight change during treatment
NATIVE biomarker analysis: serum signatures of histologic response to lanifibranor
“Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings support utilizing a similar approach in a larger sample size (NATiV3, NCT03008070).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator therapies: resmetirom response in participants receiving background GLP-1 RA therapy
Comparator therapies: tirzepatide histologic response and metabolic change by type 2 diabetes status (SYNERGY-NASH post hoc analysis)
“Few MASH studies have compared histological responses in participants with T2D with those who do not have T2D.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In participants included in the present analyses, placebo-adjusted body weight reduction with tirzepatide 15 mg was nonsignificantly (P = 0.128 for interaction term) lower in participants with T2D (−14.5%) versus those without T2D (−22.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the association between fibrosis improvement response and changes in metabolic parameters such as HbA1c, body weight, and adiponectin were driven mainly by significant associations in the T2D group and were not observed in the non-T2D group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator therapies: dapagliflozin response by age and sex (DEAN)
“Thirdly, a high proportion of male and relatively younger participants were recruited in this trial because they may be more willing to accept liver biopsy at screening. Although the results showed no age and sex differences of dapagliflozin on MASH improvement, female and the older patients were underrepresented in the current study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator therapies: bariatric surgery histologic response in Asian countries
Care management intervention strategies
Multidisciplinary care model across primary care, endocrinology, and hepatology (AASLD 2023)
“Optimal care of the patient with NAFLD requires a multidisciplinary approach. The majority of patients are in the primary care/endocrine setting, in which management of medical comorbidities should be optimized, with preference given to treatments for type 2 diabetes mellitus, hypertension, or obesity that likely also have beneficial effects on NAFLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The role of the gastroenterologist/hepatologist includes more comprehensive liver risk stratification, exclusion of other liver diseases, and a focus on liver-directed therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients should undergo dietary/nutritional assessment and a plan established for regular follow-up independent of gastroenterology/hepatology visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multidisciplinary management recommendation (EASL-EASD-EASO)
AGA clinical care pathway: risk stratification in primary care and hepatologist-coordinated care for high-risk patients
“As a result, FIB-4 provides a useful, inexpensive, first-line assessment of liver fibrosis for use in primary care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that these patients be managed by a multidisciplinary team closely coordinated by a hepatologist who can monitor for cirrhosis, HCC, and other cirrhosis-related complications. In these patients, we recommend aggressive lifestyle changes aimed at long-term weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ADA Standards of Care 2026: screening and referral of adults with type 2 diabetes or prediabetes
“Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Refer adults with type 2 diabetes or prediabetes at higher risk for significant liver fibrosis (i.e., as indicated by FIB-4, liver stiffness measurement, or ELF) to a gastroenterologist or hepatologist for further evaluation and management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-treatment monitoring and discontinuation criteria for resmetirom at 12 months (AASLD October 2024 update)
Response and futility assessment for semaglutide at 72 weeks (AASLD November 2025 update)
Treatment response definition at 1 year (updated global consensus 2026)
“The panel endorsed a sequential risk-stratification strategy beginning with Fibrosis-4 Index (FIB-4) as the first-line assessment, followed by vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) testing for secondary stratification.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment response at 1 year was defined as a ≥30% reduction in liver stiffness or a ≥0.5-point reduction in ELF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacist-led prescription pathway for resmetirom in a US health system
“Our health system allocated a senior and experienced PharmD pharmacist (Phoebe Shackelford) to champion the resmetirom prescription pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our prescription pathway effectively dispensed resmetirom to nearly all patients who were prescribed resmetirom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One in 6 patients discontinued resmetirom, primarily due to side effects. This high discontinuation rate may be mitigated by modifying our follow-up from” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utilization management: national formulary prior authorization criteria for resmetirom and semaglutide in MASH
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
In the NATIVE trial at week 24, in the full analysis population with missing data handled by multiple imputation, a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) occurred in 55% of participants receiving lanifibranor 1200 mg (significant) and 48% receiving 800 mg (not significant), compared with 33% receiving placebo; resolution of NASH without worsening of fibrosis occurred in 49%, 39%, and 22%. The company topline release reported the primary end point in the ITT population as 49% (1200 mg, P=0.004), 41% (800 mg, P=0.061), and 27% (placebo). The trial publication states that fibrosis is the primary predictor of complications and death in NASH and that regression of fibrosis is associated with decreased risk of liver-related events.
Evidence linking fibrosis stage to outcomes comes from pooled cohort studies and models. Across cohort studies of biopsy-proven NAFLD, stage 3 to 4 fibrosis carried higher all-cause (HR 3.32) and liver-related mortality (HR 10.40) than stage 0 to 2. The estimated time to progress by one stage was 13.3 years from F2 and 22.2 years from F3, and the time to regress by one stage was 12.5 years from F3 and 20.4 years from F2. A US model estimated that a hypothetical therapy halting fibrosis progression in MASLD would reduce cases of decompensated cirrhosis by 11-39%, hepatocellular carcinoma by 10-34%, and liver-related deaths by 8-31%. The AASLD resmetirom update states that stabilization of fibrosis may portend important long-term benefits. The EASL guideline states that agents receiving accelerated approval for MASH must demonstrate beneficial effects on clinical outcomes (mortality, decompensation, liver transplantation, and hepatocellular carcinoma).
NATIVE: histologic response at week 24, full analysis population with multiple imputation
Fibrosis regression as a predictor of reduced liver-related events (NATIVE discussion)
Mortality by fibrosis stage in biopsy-proven NAFLD (meta-analysis of 14 studies)
“Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08–1.98), stage 3; HR, 1.96 (95% CI, 1.41–2.72), and stage 4; HR, 3.66 (95% CI, 2.65–5.05). Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44–11.5), stage 3; HR, 7.59 (95% CI, 2.80–20.5), and stage 4; HR, 15.1 (95% CI, 5.27–43.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stage 3 to 4 fibrosis had a higher all-cause (HR, 3.32) and liver-related mortality (HR, 10.40) compared with stage 0 to 2 fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Untreated progression and regression times per fibrosis stage (meta-analysis of 54 studies)
“Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3 and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled US outcomes of a therapy that halts fibrosis progression in MASLD with moderate-to-advanced fibrosis
“The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote